https://www.alacrita.com/news/alacrita-2012-life-science-charity-auction2019-04-29https://www.alacrita.com/case-studies/gene-therapy-preclinical-cmc-and-regulatory-strategy2026-03-28https://www.alacrita.com/case-studies/assessing-commercial-viability-biosimilars2019-04-29https://www.alacrita.com/case-studies/providing-diagnostics-due-diligence2019-08-02https://www.alacrita.com/blog/micrornas-as-drug-targets-historical-challenges-and-the-way-forward2019-04-30https://www.alacrita.com/blog/the-rise-and-rise-of-antibody-drug-conjugateshttps://www.alacrita.com/hubfs/antibody.jpgantibodyantibody2023-04-26https://www.alacrita.com/news/li-zeng-based-in-beijing-joins-alacrita2019-04-29https://www.alacrita.com/case-studies/comparing-clinical-response-rates-for-tumour-infiltrating-lymphocytes2023-11-14https://www.alacrita.com/case-studies/transatlantic-payer-and-pricing-research2024-02-19https://www.alacrita.com/case-studies/glioblastoma-landscape2022-08-15https://www.alacrita.com/case-studies/development-plan-for-novel-small-molecule-for-cancer2023-11-14https://www.alacrita.com/case-studies/due-diligence-of-a-clinical-stage-therapeutic2022-06-21https://www.alacrita.com/alacrita-expert-network2026-02-20https://www.alacrita.com/blog/extracellular-vesicle-therapeutics2024-05-13https://www.alacrita.com/whitepapers/ipscs-to-improve-cns-modelinghttps://www.alacrita.com/hubfs/iPSCs-Figure1.jpgiPSCsFigure1iPSCsFigure1https://www.alacrita.com/hubfs/iPSCs-Figure2.jpgiPSCsFigure2iPSCsFigure2https://www.alacrita.com/hubfs/synapses.jpgsynapsessynapses2022-06-09https://www.alacrita.com/case-studies/orphan-drug-commercialization-consulting2019-04-29https://www.alacrita.com/case-studies/due-diligence-of-pluripotent-stem-cell-technology-in-disease-modeling2024-10-14https://www.alacrita.com/news/bill-slichenmyer-alacrita-partner-reflects-on-sitc-2016-conference2019-04-29https://www.alacrita.com/case-studies/value-proposition-and-pricing-for-novel-gi-treatment2024-02-19https://www.alacrita.com/case-studies/market-access-plan-for-novel-kidney-disorder-treatment2023-07-21https://www.alacrita.com/case-studies/pharma-manufacturing-consultancy-company-developing-novel-small-molecule2022-08-17https://www.alacrita.com/case-studies/oncology-development-plan-support-fundraising2019-04-29https://www.alacrita.com/whitepapers/valuing-pharmaceutical-assets-when-to-use-npv-vs-rnpvhttps://www.alacrita.com/hubfs/Imported_Blog_Media/Pharma-Valuations-NPV.jpgPharmaValuationsNPVPharmaValuationsNPVhttps://www.alacrita.com/hubfs/Imported_Blog_Media/Valuations-of-ImmunoGens-IPRD-Assets.jpgValuationsofImmunoGensIPRDAssetsValuationsofImmunoGensIPRDAssetshttps://www.alacrita.com/hubfs/Imported_Blog_Media/Johnson-and-Johnson%E2%80%99s-Recent-IPRD-Asset-Acquisition-Valuations.jpgJohnsonandJohnsonsRecentIPRDAssetAcquisitionValuationsJohnsonandJohnsonsRecentIPRDAssetAcquisitionValuationshttps://www.alacrita.com/hubfs/Imported_Blog_Media/Pharma-Valuations-Starting-Criteria.jpgPharmaValuationsStartingCriteriaPharmaValuationsStartingCriteriahttps://www.alacrita.com/hubfs/Imported_Blog_Media/Pharma-NPV-rNPV-Valuations.jpgPharmaNPVrNPVValuationsPharmaNPVrNPVValuationshttps://www.alacrita.com/hubfs/Imported_Blog_Media/Pharma-Valuations-WACC-Based-on-Biotech-Firm-Stage.jpgPharmaValuationsWACCBasedonBiotechFirmStagePharmaValuationsWACCBasedonBiotechFirmStagehttps://www.alacrita.com/hubfs/Imported_Blog_Media/Pharma-Valuations-rNPV-Discount-Rates.jpgPharmaValuationsrNPVDiscountRatesPharmaValuationsrNPVDiscountRateshttps://www.alacrita.com/hubfs/Imported_Blog_Media/Pharma-Valuations-NPV-Discount-Rates-Based-on-Project-Stage.jpgPharmaValuationsNPVDiscountRatesBasedonProjectStagePharmaValuationsNPVDiscountRatesBasedonProjectStagehttps://www.alacrita.com/hubfs/Imported_Blog_Media/Pharma-Valuations-rNPV.jpgPharmaValuationsrNPVPharmaValuationsrNPV2019-10-15https://www.alacrita.com/case-studies/due-diligence-on-a-series-of-investments-in-oncology-and-genetic-diseases2026-02-11https://www.alacrita.com/case-studies/providing-due-diligence-prescription-surgical-product2024-03-06https://www.alacrita.com/news/alacritaattending-jpmorgan-biotech-showcase2019-04-29https://www.alacrita.com/case-studies/global-sales-forecast-for-a-small-molecule-in-hepatocellular-carcinoma2023-11-15https://www.alacrita.com/blog/why-is-it-so-daunting-for-us-biotech-and-pharma-to-launch-drugs-in-europe-themselves2019-04-29https://www.alacrita.com/case-studies/technical-and-commercial-due-diligence-for-two-pipeline-products2026-02-11https://www.alacrita.com/blog/the-risk-reward-balance-in-drug-repurposinghttps://www.alacrita.com/hubfs/lab.jpglablab2023-01-19https://www.alacrita.com/case-studies/gene-therapy-manufacturing-license-negotiation2022-08-16https://www.alacrita.com/blog/senolytics-taking-aim-at-ageing-cells2019-04-29https://www.alacrita.com/our-services/pharma-business-development2026-03-19https://www.alacrita.com/case-studies/adeno-associated-virus-vector-manufacturing-landscape2024-05-16https://www.alacrita.com/careers-02024-12-13https://www.alacrita.com/case-studies/kol-payer-market-research-for-small-molecule-in-aortic-valve-stenosis2024-02-19https://www.alacrita.com/case-studies/scouting-early-stage-oncology-opportunities2019-04-29https://www.alacrita.com/biotech-vc-support2025-05-09https://www.alacrita.com/blog/targeted-dermatology-drug-developmenthttps://www.alacrita.com/hubfs/Dermatology%20LI%20Post%20Graphic%20v2.jpgDermatologyLIPostGraphicv2DermatologyLIPostGraphicv2https://www.alacrita.com/hubfs/targeted%20dermatology%20graphic.pngtargeteddermatologygraphictargeteddermatologygraphic2024-10-17https://www.alacrita.com/consultants/peter-g-traber2021-06-10https://www.alacrita.com/case-studies/value-potential-of-a-novel-cell-based-assay2023-07-20https://www.alacrita.com/our-services2025-12-31https://www.alacrita.com/case-studies/commercial-viability-of-a-bacterial-biomarker-test2023-07-20https://www.alacrita.com/case-studies/partnering-support2019-04-29https://www.alacrita.com/blog/when-to-consider-new-drug-pricing-strategyhttps://www.alacrita.com/hubfs/Drug%20Pricing%20-%20LI.jpgDrugPricingLIDrugPricingLI2023-10-30https://www.alacrita.com/news/saadia-basharat-attending-superbugs-and-superdrugs-conference-london2019-04-29https://www.alacrita.com/blog/post-ema-approval-how-soon-can-products-be-sold2019-04-29https://www.alacrita.com/case-studies/opportunity-mapping-in-advanced-cholangiocarcinoma2023-01-31https://www.alacrita.com/case-studies/developing-payer-advisory-board-novel-medical-device2019-10-17https://www.alacrita.com/hematology-drug-development-consultantshttps://www.alacrita.com/hubfs/image-png-Mar-06-2024-02-30-57-3474-PM.pngimagepngMar0620240230573474PMimagepngMar0620240230573474PMhttps://www.alacrita.com/hubfs/image-png-Mar-06-2024-02-31-06-2414-PM.pngimagepngMar0620240231062414PMimagepngMar0620240231062414PM2024-03-06https://www.alacrita.com/case-studies/european-payer-research2019-11-05https://www.alacrita.com/case-studies/clinical-development-regulatory-pathway-gene-therapy-product2024-05-13https://www.alacrita.com/our-services/biotech-business-plans-fundraising2024-09-03https://www.alacrita.com/case-studies/due-to-neutralizing-antibodies-nabs2025-01-20https://www.alacrita.com/case-studies/preclinical-due-diligence-of-novel-live-biotherapeutic2026-03-28https://www.alacrita.com/case-studies/valuation-of-rx-and-otc-products-for-an-investor2024-03-06https://www.alacrita.com/case-studies/opportunity-assessment-for-functional-rna-protein-arrays2023-11-01https://www.alacrita.com/case-studies/investor-due-diligence-on-clinical-stage-oncology-therapeutic-company2019-08-05https://www.alacrita.com/consultants/saadia-anastasiouhttps://www.alacrita.com/hubfs/Saadia%20headshot%202021.jpgSaadiaheadshot2021Saadiaheadshot20212025-05-08https://www.alacrita.com/case-studies/preparing-expert-review-paper2019-04-29https://www.alacrita.com/case-studies/investor-due-diligence-pharma-business-development-case-studies2020-09-16https://www.alacrita.com/blog/gene-therapy-suspending-vector-immunity-and-facilitating-re-dosinghttps://www.alacrita.com/hubfs/AdobeStock_267117635.jpegAdobeStock267117635AdobeStock2671176352019-12-02https://www.alacrita.com/whitepapers/antimicrobial-resistance-drug-development-landscapehttps://www.alacrita.com/hubfs/due-diligence-bg.jpgduediligencebgduediligencebg2025-12-02https://www.alacrita.com/case-studies/interim-chief-medical-officer-for-antiviral-drug-company2024-09-03https://www.alacrita.com/case-studies/providing-business-development-deal-support-antibiotics2019-04-29https://www.alacrita.com/case-studies/internal-dd-and-investor-readiness-for-pre-clinical-biotech-company2023-11-16https://www.alacrita.com/case-studies/advanced-wound-care-regulatory-support2019-04-29https://www.alacrita.com/case-studies/business-plan-and-fundraising-for-cell-therapy-company2026-02-17https://www.alacrita.com/case-studies/interim-chief-medical-officer-support-for-an-immuno-oncology-biopharma-company2022-08-10https://www.alacrita.com/case-studies/deal-benchmarks-negotiating-positions-ai-drug-discovery2024-05-13https://www.alacrita.com/case-studies/valuation-of-a-lead-pipeline-agent2023-01-20https://www.alacrita.com/case-studies/business-plan-for-opioid-overdose-detection-device2023-07-21https://www.alacrita.com/case-studies/regulatory-due-diligence-for-a-fib-development-drug2024-02-19https://www.alacrita.com/cmc-consulting-services2026-03-19https://www.alacrita.com/case-studies/medical-device-technology-assessment2019-04-29https://www.alacrita.com/case-studies/development-plan-for-a-bio-scaffold-in-spinal-cord-injury2024-02-09https://www.alacrita.com/case-studies/payer-advisory-board2019-10-22https://www.alacrita.com/whitepapers/pharma-licensing-and-partnering-interestshttps://www.alacrita.com/hubfs/glass-helix.jpgglasshelixglasshelixhttps://www.alacrita.com/hubfs/image-png-Aug-16-2023-12-49-47-0740-PM.pngimagepngAug1620231249470740PMimagepngAug1620231249470740PMhttps://www.alacrita.com/hubfs/image-png-Aug-16-2023-11-54-18-7559-AM.pngimagepngAug1620231154187559AMimagepngAug1620231154187559AMhttps://www.alacrita.com/hubfs/image-png-Aug-16-2023-11-58-11-0629-AM.pngimagepngAug1620231158110629AMimagepngAug1620231158110629AM2023-08-17https://www.alacrita.com/case-studies/clinical-due-diligence-of-an-nk-cell-therapy2023-11-16https://www.alacrita.com/case-studies/strategic-ip-portfolio-review-tto2025-03-12https://www.alacrita.com/news/edward-garmey-md-will-moderate-a-panel-at-bio-europe2019-04-29https://www.alacrita.com/news/pharma-supply-chain-book-discount-available2019-04-29https://www.alacrita.com/case-studies/evaluating-pipeline-agreement-platform-tech-company2022-08-18https://www.alacrita.com/careers/administrative-and-other-support/https://www.alacrita.com/hubfs/alacrita_homepage.jpgalacritahomepagealacritahomepage2019-05-01https://www.alacrita.com/consultants/simon-turner2025-04-04https://www.alacrita.com/case-studies/advising-intellectual-property-precision-medicine-diagnostics2019-04-29https://www.alacrita.com/our-services/pharmaceutical-new-product-planning2024-09-03https://www.alacrita.com/case-studies/applying-for-prime-ema-status-in-the-eu2023-11-14https://www.alacrita.com/case-studies/scouting-gi-disease-assets-for-in-licensing2024-05-24https://www.alacrita.com/careers2023-03-02https://www.alacrita.com/news/alacrita-promotes-saadia-basharat-phd-to-head-of-west-coast-consulting2023-03-16https://www.alacrita.com/whitepapers/senotherapy-the-battle-for-quality-vs-quantity-of-lifehttps://www.alacrita.com/hubfs/senotherapy-aad-graph.jpgsenotherapyaadgraphsenotherapyaadgraphhttps://www.alacrita.com/hubfs/Senescencent-cell.pngSenescencentcellSenescencentcellhttps://www.alacrita.com/hubfs/AI%20post%20image%20-%20no%20text.jpgAIpostimagenotextAIpostimagenotexthttps://www.alacrita.com/hubfs/senotherapy-investment.jpgsenotherapyinvestmentsenotherapyinvestment2024-09-13https://www.alacrita.com/case-studies/glycan-biomarker-discovery-market-research-in-north-america2023-07-31https://www.alacrita.com/case-studies/development-support-for-first-in-class-pediatric-oncology-drug2019-04-29https://www.alacrita.com/blog/navigating-the-clinical-drug-development-processhttps://www.alacrita.com/hubfs/alacrita_homepage.jpgalacritahomepagealacritahomepage2024-12-02https://www.alacrita.com/case-studies/pharmaceutical-supply-chain-planning2024-01-12https://www.alacrita.com/whitepapers/cell-therapy-for-autoimmune-diseaseshttps://www.alacrita.com/hubfs/cell-therapy-graphic.jpgcelltherapygraphiccelltherapygraphichttps://www.alacrita.com/hubfs/cell-therapy-programs-by-dev-stage.jpgcelltherapyprogramsbydevstagecelltherapyprogramsbydevstagehttps://www.alacrita.com/hubfs/cell-therapy-programs-by-indications.jpgcelltherapyprogramsbyindicationscelltherapyprogramsbyindicationshttps://www.alacrita.com/hubfs/autologous-alloegeneic-cell-therapy.jpegautologousalloegeneiccelltherapyautologousalloegeneiccelltherapyhttps://www.alacrita.com/hubfs/cell-therapy-development-programs.jpgcelltherapydevelopmentprogramscelltherapydevelopmentprograms2021-02-11https://www.alacrita.com/case-studies/providing-phase-lll-ready-radiolabelled-antibody-due-diligence2024-02-19https://www.alacrita.com/case-studies/creating-a-commercial-development-plan-for-a-t-cell-therapy2024-02-19https://www.alacrita.com/case-studies/developing-vaccine-products2023-08-15https://www.alacrita.com/whitepapers/adeno-associated-virus-gene-therapy-landscapehttps://www.alacrita.com/hubfs/AAV-Figure-2.jpgAAVFigure2AAVFigure2https://www.alacrita.com/hubfs/AAV-Figure-5.jpgAAVFigure5AAVFigure5https://www.alacrita.com/hubfs/AAV-Figure-1.pngAAVFigure1AAVFigure1https://www.alacrita.com/hubfs/AAV-Table-1.jpgAAVTable1AAVTable1https://www.alacrita.com/hubfs/AAV-Figure-4.jpgAAVFigure4AAVFigure4https://www.alacrita.com/hubfs/AAV-Figure-3-1.jpgAAVFigure31AAVFigure31https://www.alacrita.com/hubfs/AAV-Table-2-1.jpgAAVTable21AAVTable212019-10-16https://www.alacrita.com/case-studies/due-diligence-cancer-vaccine-phase-32023-08-15https://www.alacrita.com/our-services/pharmaceutical-regulatory-affairs2024-07-23https://www.alacrita.com/blog/bio-europe-2017-clinical-trials-early-stage-oncology-developmenthttps://www.alacrita.com/hubfs/Imported_Blog_Media/tamara-talking-to-the-audience.jpgtamaratalkingtotheaudiencetamaratalkingtotheaudiencehttps://www.alacrita.com/hubfs/Imported_Blog_Media/carlos-speaking-about-his-expereiences.jpgcarlosspeakingabouthisexpereiencescarlosspeakingabouthisexpereienceshttps://www.alacrita.com/hubfs/Imported_Blog_Media/BIO-Europe-2017.jpgBIOEurope2017BIOEurope2017https://www.alacrita.com/hubfs/Imported_Blog_Media/bob-talking-to-the-audience.jpgbobtalkingtotheaudiencebobtalkingtotheaudiencehttps://www.alacrita.com/hubfs/Imported_Blog_Media/gemma-speaking-about-her-expereiences.jpggemmaspeakingaboutherexpereiencesgemmaspeakingaboutherexpereienceshttps://www.alacrita.com/hubfs/Imported_Blog_Media/sonal-talking-to-the-audience.jpgsonaltalkingtotheaudiencesonaltalkingtotheaudience2019-04-29https://www.alacrita.com/blog/do-price-and-value-assumptions-belong-in-target-product-profileshttps://www.alacrita.com/hubfs/focus.jpgfocusfocus2023-04-13https://www.alacrita.com/our-services/pharmaceutical-licensing-asset-scouting2024-04-11https://www.alacrita.com/case-studies/virtual-stewardship-of-a-targeted-cancer-therapy-to-an-ind-submission2023-04-28https://www.alacrita.com/whitepapers/live-biotherapeutic-products-landscape-analysishttps://www.alacrita.com/hubfs/image-png-Oct-28-2025-06-09-39-3670-PM.pngimagepngOct2820250609393670PMimagepngOct2820250609393670PMhttps://www.alacrita.com/hubfs/image-png-Oct-28-2025-05-55-10-2810-PM.pngimagepngOct2820250555102810PMimagepngOct2820250555102810PMhttps://www.alacrita.com/hubfs/due-diligence-bg.jpgduediligencebgduediligencebghttps://www.alacrita.com/hubfs/image-png-Oct-28-2025-06-11-53-2224-PM.pngimagepngOct2820250611532224PMimagepngOct2820250611532224PMhttps://www.alacrita.com/hubfs/image-png-Oct-28-2025-06-29-34-0645-PM.pngimagepngOct2820250629340645PMimagepngOct2820250629340645PMhttps://www.alacrita.com/hubfs/image-png-Oct-28-2025-05-50-09-6427-PM.pngimagepngOct2820250550096427PMimagepngOct2820250550096427PM2025-10-30https://www.alacrita.com/case-studies/independently-reviewing-clinical-trial-data2019-08-09https://www.alacrita.com/immunology-drug-development-consultantshttps://www.alacrita.com/hubfs/image-png-Apr-04-2024-01-06-01-0459-PM.pngimagepngApr0420240106010459PMimagepngApr0420240106010459PMhttps://www.alacrita.com/hubfs/image-png-Apr-04-2024-01-05-52-5472-PM.pngimagepngApr0420240105525472PMimagepngApr0420240105525472PM2024-04-04https://www.alacrita.com/careers/functional-specialists/https://www.alacrita.com/hubfs/alacrita_homepage.jpgalacritahomepagealacritahomepage2024-02-29https://www.alacrita.com/blog/technology-transfer-office-tto-biotech-guidancehttps://www.alacrita.com/hubfs/helix-sm.jpghelixsmhelixsm2024-02-09https://www.alacrita.com/interim-chief-medical-officer-serviceshttps://www.alacrita.com/hubfs/cmo-graphic-4-Jan-22-2024-09-38-57-8658-PM.pngcmographic4Jan2220240938578658PMcmographic4Jan2220240938578658PM2024-01-23https://www.alacrita.com/our-services/regulatory-12022-03-31https://www.alacrita.com/whitepapers/re-profiling-a-hidden-threat-to-originators2019-04-29https://www.alacrita.com/case-studies/rd-strategy-in-radiopharmaceuticals2019-04-29https://www.alacrita.com/news/rob-johnson-attending-bd-boston2019-04-29https://www.alacrita.com/case-studies/cmc-consulting-for-a-company-developing-a-peptide2025-01-27https://www.alacrita.com/case-studies/university-ip-portfolio-triage2024-05-16https://www.alacrita.com/case-studies/providing-life-science-reagents-due-diligence2024-02-19https://www.alacrita.com/case-studies/start-up-support-and-funding2026-02-17https://www.alacrita.com/whitepapers/leveraging-diagnostics-realize-full-potential-precision-oncology2019-04-29https://www.alacrita.com/news/appoints-stuart-hendry-as-associate-partner-to-strengthen-medtech-practice2019-04-29https://www.alacrita.com/case-studies/due-diligence-on-dna-damage-response-assets2023-11-29https://www.alacrita.com/case-studies/clinical-landscape-analysis-for-tumor-infiltrating-lymphocytes2024-09-03https://www.alacrita.com/case-studies/510k-consulting-for-respiratory-medical-device2022-08-15https://www.alacrita.com/consultants/stuart-hendry2019-04-19https://www.alacrita.com/case-studies/development-refinement-of-a-patient-reported-outcome-pro-strategy2019-10-14https://www.alacrita.com/case-studies/regulatory-due-diligence2019-04-29https://www.alacrita.com/cns-drug-development-consultantshttps://www.alacrita.com/hubfs/image-png-Feb-09-2024-09-04-56-9539-PM.pngimagepngFeb0920240904569539PMimagepngFeb0920240904569539PMhttps://www.alacrita.com/hubfs/image-png-Feb-09-2024-09-05-02-8729-PM.pngimagepngFeb0920240905028729PMimagepngFeb0920240905028729PM2024-02-09https://www.alacrita.com/case-studies/providing-due-diligence-alzheimers-treatment2024-02-09https://www.alacrita.com/case-studies/due-diligence-of-gene-therapy-to-support-in-licensing2023-02-15https://www.alacrita.com/case-studies/neuroscience-due-diligence2019-04-29https://www.alacrita.com/case-studies/due-diligence-valuation-and-licensing-of-an-infectious-disease-asset2024-07-10https://www.alacrita.com/academic-commercialization2025-07-10https://www.alacrita.com/life-science2019-10-28https://www.alacrita.com/case-studies/monetizing-oncology-royalty-streams2019-10-09https://www.alacrita.com/case-studies/distressed-company-analysis-for-asset-scouting-in-licensing2023-07-20https://www.alacrita.com/blog/colin-miller-medical-imaging-consultant-presents-poster-oarsi-meetinghttps://www.alacrita.com/hubfs/Imported_Blog_Media/Standardization-of-imaging-reads-for-eligibility-assessment-of-patients.gifStandardizationofimagingreadsforeligibilityassessmentofpatientsStandardizationofimagingreadsforeligibilityassessmentofpatients2019-04-29https://www.alacrita.com/whitepapers/preclinical-development-beyond-in-vivo-modelshttps://www.alacrita.com/hubfs/change-in-survival.jpgchangeinsurvivalchangeinsurvivalhttps://www.alacrita.com/hubfs/researcher.jpgresearcherresearcherhttps://www.alacrita.com/hubfs/publications-2.jpgpublications2publications22022-02-02https://www.alacrita.com/consultants/pierre-dodion-biotech-consultanthttps://www.alacrita.com/hubfs/pierre-dodion.jpgpierredodionpierredodion2025-04-04https://www.alacrita.com/case-studies/payer-research-pricing-strategy-anemia2024-02-19https://www.alacrita.com/case-studies/biotech-partnership-due-diligence-womens-health2025-07-02https://www.alacrita.com/case-studies/commercialization-advice-rare-diseases2019-04-29https://www.alacrita.com/case-studies/oncology-clinical-expert-input-and-asset-valuation2023-11-15https://www.alacrita.com/whitepapers/biotech-in-israel-a-land-of-promisehttps://www.alacrita.com/hubfs/Imported_Blog_Media/IsraelBiotech.pngIsraelBiotechIsraelBiotech2019-04-29https://www.alacrita.com/case-studies/conducting-reality-check-ongoing-cardiology-project2024-02-19https://www.alacrita.com/case-studies/in-licensing-support-and-asset-scouting-in-cns2025-01-03https://www.alacrita.com/whitepapers/exosome-and-extracellular-vesical-based-therapeuticshttps://www.alacrita.com/hubfs/oncology-image-1.jpgoncologyimage1oncologyimage1https://www.alacrita.com/hubfs/exosomes-graphic-1.jpgexosomesgraphic1exosomesgraphic1https://www.alacrita.com/hubfs/exosome-key-players.jpgexosomekeyplayersexosomekeyplayershttps://www.alacrita.com/hubfs/exosome-payload-1.jpgexosomepayload1exosomepayload12022-02-01https://www.alacrita.com/case-studies/technical-due-diligence-for-a-competitve-ma-transaction2024-05-16https://www.alacrita.com/our-services/operations-management2019-04-26https://www.alacrita.com/case-studies/providing-immuno-oncology-medical-and-clinical-support2020-07-20https://www.alacrita.com/case-studies/new-in-licensing-opportunities-in-oncology2020-09-15https://www.alacrita.com/blog/brexit-options-uk-registered-mahs2019-04-29https://www.alacrita.com/biotech-consulting-support2024-09-17https://www.alacrita.com/whitepapers/deal-watch-annual-review-20112019-04-29https://www.alacrita.com/case-studies/due-diligence-of-late-stage-gene-therapy-asset2022-08-16https://www.alacrita.com/case-studies/biotech-partnership-dispute-expert-witness2025-10-23https://www.alacrita.com/case-studies/sales-forecast-for-nanoparticle-drug-conjugate2024-07-10https://www.alacrita.com/news/alacrita-appoints-anna-casse-4th-managing-partner-strengthen-commercial-advisory-services-build-european-launch-platform2019-04-29https://www.alacrita.com/case-studies/expert-witness-to-support-pharma-litigation-process2022-06-21https://www.alacrita.com/gene-therapy-consultinghttps://www.alacrita.com/hubfs/image-png-Aug-15-2022-06-59-49-22-PM.pngimagepngAug15202206594922PMimagepngAug15202206594922PMhttps://www.alacrita.com/hubfs/image-png-Aug-15-2022-06-59-58-14-PM.pngimagepngAug15202206595814PMimagepngAug15202206595814PM2024-05-24https://www.alacrita.com/case-studies/market-landscape-exercise-for-three-oncology-university-based-therapeutics2024-05-16https://www.alacrita.com/antibody-adc-therapy-consultinghttps://www.alacrita.com/hubfs/image-png-Aug-10-2022-11-03-01-08-AM.pngimagepngAug10202211030108AMimagepngAug10202211030108AMhttps://www.alacrita.com/hubfs/image-png-Aug-23-2022-10-01-01-34-AM.pngimagepngAug23202210010134AMimagepngAug23202210010134AM2024-01-26https://www.alacrita.com/case-studies/providing-clinical-due-diligence-novel-biologic-treat-respiratory-disease2019-04-29https://www.alacrita.com/news/michael-lombardo-joins-alacrita-consultinghttps://www.alacrita.com/hubfs/Welcome%20Post%20-%20Michael.jpgWelcomePostMichaelWelcomePostMichael2024-10-09https://www.alacrita.com/case-studies/assessing-ophthalmic-market2019-10-09https://www.alacrita.com/news/mark-wickham-and-stuart-hendry-attending-med-tech-innovation-expo-coventry-uk2019-04-29https://www.alacrita.com/consultantshttps://www.alacrita.com/hubfs/Saadia-basharat-biotech-consultant-2.jpgSaadiabasharatbiotechconsultant2Saadiabasharatbiotechconsultant2https://www.alacrita.com/hubfs/mark-philip.jpgmarkphilipmarkphiliphttps://www.alacrita.com/hubfs/gary-mansfield.jpggarymansfieldgarymansfieldhttps://www.alacrita.com/hubfs/Brian-McGuinness-2.jpgBrianMcGuinness2BrianMcGuinness2https://www.alacrita.com/hubfs/anthony-walker-managing-partner.jpganthonywalkermanagingpartneranthonywalkermanagingpartnerhttps://www.alacrita.com/hubfs/Michael-Lombardo-new-3.jpgMichaelLombardonew3MichaelLombardonew3https://www.alacrita.com/hubfs/lucas-rodriguez-alacrita-1.jpglucasrodriguezalacrita1lucasrodriguezalacrita1https://www.alacrita.com/hubfs/Cort-HeadShot-BW.jpgCortHeadShotBWCortHeadShotBWhttps://www.alacrita.com/hubfs/pierre-dodion.jpgpierredodionpierredodion2026-02-11https://www.alacrita.com/case-studies/providing-an-oncology-cell-therapy-reality-check2019-08-01https://www.alacrita.com/whitepapers/biotech-vc-early-formation-underpricedhttps://www.alacrita.com/hubfs/due-diligence-bg.jpgduediligencebgduediligencebg2026-01-12https://www.alacrita.com/early-stage-biotech-investor-partnering-materials2026-02-13https://www.alacrita.com/case-studies/dermatology-due-diligence-valuation2019-04-29https://www.alacrita.com/news/alacrita-offers-asset-scouting-servi2019-04-29https://www.alacrita.com/case-studies/due-diligence-on-life-cycle-management-strategies-for-acute-care-assets2023-11-29https://www.alacrita.com/case-studies/providing-rubidium-82-due-diligence2024-02-19https://www.alacrita.com/case-studies/providing-regulatory-strategy-for-t-cell-therapy2022-08-15https://www.alacrita.com/blog/healthcare-rationing-simply-prioritization2019-04-29https://www.alacrita.com/news/charity_auction_2011https://www.alacrita.com/hubfs/Imported_Blog_Media/Camfed-Logo-300x105.jpgCamfedLogo300x105CamfedLogo300x1052019-04-29https://www.alacrita.com/case-studies/advising-chief-medical-officer2019-04-29https://www.alacrita.com/case-studies/pre-due-diligence-on-repurposed-cns-products2024-02-19https://www.alacrita.com/blog/drug-repurposinghttps://www.alacrita.com/hubfs/dna.jpgdnadna2023-08-09https://www.alacrita.com/case-studies/commercialisation-roadmap-for-a-new-qpcr-assay2019-10-23https://www.alacrita.com/case-studies/valuation-of-dna-vaccine-pipeline-for-biotech-company2024-08-06https://www.alacrita.com/case-studies/out-licensing-support-for-a-dengue-vaccine2024-01-12https://www.alacrita.com/asset-partnering2019-04-26https://www.alacrita.com/our-services/due-diligencehttps://www.alacrita.com/hubfs/Due%20Diligence%20-%20LI.jpgDueDiligenceLIDueDiligenceLIhttps://www.alacrita.com/hubfs/due-diligence-bg-1.jpgduediligencebg1duediligencebg12026-02-11https://www.alacrita.com/case-studies/commercial-attractiveness-biomarkers-start2019-04-29https://www.alacrita.com/news/edward-garmey-lecturing-at-harvard-medical-school-on-checkpoint-inhibitors2019-04-29https://www.alacrita.com/case-studies/deal-analysis-for-an-anti-anaemia-product2024-02-19https://www.alacrita.com/case-studies/providing-expert-due-diligence-reformulation-marketed-biologic2019-10-14https://www.alacrita.com/case-studies/technical-commercial-review-of-anti-inflammatory-peptide2022-08-17https://www.alacrita.com/our-services/pharmaceutical-biotech-valuations2024-08-06https://www.alacrita.com/case-studies/radiopharma-opportunity-mapping-and-landscape2023-08-15https://www.alacrita.com/news/alacrita-attending-sponsoring-biotech-showcase-at-jpm-20192023-03-20https://www.alacrita.com/our-services/virtual-biotech2025-09-03https://www.alacrita.com/news/martin-pue-joins-the-alacrita-team2019-04-29https://www.alacrita.com/case-studies/investor-due-diligence-on-preclinical-stage-vaccine-platform-technology2023-08-18https://www.alacrita.com/case-studies/assessing-the-potential-of-a-novel-extracellular-vesicle-technology2023-01-31https://www.alacrita.com/blog/rnpv-valuations-pharma-deal-term-negotiationshttps://www.alacrita.com/hubfs/rNPV%20Deal%20Terms%20-%20LI%20Image.jpgrNPVDealTermsLIImagerNPVDealTermsLIImage2024-05-24https://www.alacrita.com/whitepapers2025-10-28https://www.alacrita.com/case-studies/appealing-fda-refusal-of-an-orphan-drug-designation-application2019-08-23https://www.alacrita.com/case-studies/deal-benchmarks-term-sheet-appraisal-for-an-early-stage-license-deal2021-01-18https://www.alacrita.com/case-studies/cmc-and-regulatory-due-diligence-for-a-medical-imaging-agent2024-08-06https://www.alacrita.com/blog/the-hidden-pitfalls-of-unconscious-bias-in-drug-developmenthttps://www.alacrita.com/hubfs/LI%20Post%20-%20Unconscious%20Bias.jpgLIPostUnconsciousBiasLIPostUnconsciousBias2024-07-02https://www.alacrita.com/case-studies/assessing-antibody-discovery-screening-platforms2022-08-18https://www.alacrita.com/case-studies/evaluating-the-commercial-viability-of-a-novel-neonatal-therapy-approach2025-03-25https://www.alacrita.com/case-studies/on-going-dd-support-for-research-incubator-and-seed-funder2022-06-21https://www.alacrita.com/blog/pharmaceutical-patents-an-overview2022-07-19https://www.alacrita.com/case-studies/gene-therapy-technology-opportunity-assessment2023-11-17https://www.alacrita.com/case-studies/pharma-consulting-manufacturing-transfer-scale-phase-iii-trials2019-04-29https://www.alacrita.com/case-studies/opportunity-mapping-in-myelofibrosis-for-phase-ii-product2022-08-17https://www.alacrita.com/blog/killer-experiment-university-technology-transfer2025-07-30https://www.alacrita.com/whitepapers/fda-expedited-programs-for-cancer-drug-development-dont-believe-the-doubters2019-10-15https://www.alacrita.com/blog/cancer-vaccines-ready-for-prime-time-or-another-false-dawnhttps://www.alacrita.com/hubfs/cell.jpgcellcell2023-02-03https://www.alacrita.com/news/alacrita-offering-free-mock-pitchhttps://www.alacrita.com/hubfs/Mock-pitch-1.jpgMockpitch1Mockpitch12023-05-15https://www.alacrita.com/case-studies/nash-preclinical-due-diligence-and-project-plan2021-04-29https://www.alacrita.com/case-studies/valuation-partnering-support2019-04-29https://www.alacrita.com/whitepapers/autoimmune-disease-drug-development-pipeline-and-biopharma-deals-20262026-04-01https://www.alacrita.com/case-studies/researching-eu-payers-inform-phase-iii-designs2019-04-29https://www.alacrita.com/case-studies/assessment-of-an-aav-gene-therapy2022-08-16https://www.alacrita.com/case-studies/microbiome-therapeutics-dd2023-11-16https://www.alacrita.com/news/alacrita-is-attending-bio-europe-in-cologne-germany2019-04-29https://www.alacrita.com/case-studies/valuation-and-deal-making-for-oncology-antibody2019-08-22https://www.alacrita.com/news/european-medical-devices-regulation-mdr-vitro-diagnostic-regulation-ivdr2019-04-29https://www.alacrita.com/case-studies/antiviral-gap-analysis-for-partnering-and-progression-to-ind2023-01-20https://www.alacrita.com/case-studies/biotech-due-diligence-and-product-development-planning2023-02-15https://www.alacrita.com/case-studies/due-diligence-oral-delivery-of-biopharmaceuticals2019-04-29https://www.alacrita.com/case-studies/valuation-of-novel-formulation-of-insulin-for-diabetes2023-11-15https://www.alacrita.com/technology-platform-strategy2025-07-14https://www.alacrita.com/news/alacrita-expands-medical-team-appoints-edward-g-garmey-md2019-04-29https://www.alacrita.com/our-services/pharmaceutical-regulatory-affairs-02022-09-09https://www.alacrita.com/our-services/life-science-opportunity-mapping2026-01-15https://www.alacrita.com/case-studies/due-diligence-of-plasma-protein-manufacturer-02024-02-09https://www.alacrita.com/case-studies/scouting-for-autoimmune-immunology-assets2024-07-10https://www.alacrita.com/case-studies/creating-radiopharmaceutical-investment-strategy2019-10-08https://www.alacrita.com/case-studies/valuation-of-a-repurposed-drug-for-alzheimers2024-02-19https://www.alacrita.com/news/alacrita-aggregates-the-life-science-practices-of-two-consulting-firms-and-appoints-simon-turner-ph-d-frsc-as-partner2019-04-29https://www.alacrita.com/case-studies/life-science-professional-employer-organization2019-04-29https://www.alacrita.com/case-studies/clinical-due-diligence-on-a-company-targeting-cns-indications2024-05-16https://www.alacrita.com/case-studies/aav-gene-therapy-roadmap-to-ind-for-a-cardiac-indication2024-02-19https://www.alacrita.com/news/stuart-hendry-attending-medtec-europe2019-04-29https://www.alacrita.com/consultants/lucas-rodriguezhttps://www.alacrita.com/hubfs/lucas-rodriguez-alacrita-1.jpglucasrodriguezalacrita1lucasrodriguezalacrita12025-05-05https://www.alacrita.com/whitepapers/the-emerging-landscape-of-rna-targeted-small-moleculeshttps://www.alacrita.com/hubfs/rna.jpgrnarnahttps://www.alacrita.com/hubfs/RNA-therapy-clinical-pipeline-by-stage-of-development.jpgRNAtherapyclinicalpipelinebystageofdevelopmentRNAtherapyclinicalpipelinebystageofdevelopment2021-11-11https://www.alacrita.com/case-studies/landscape-analysis-of-a-pd1-based-immunotherapy-combination2020-07-20https://www.alacrita.com/case-studies/imaging-solution-measure-injector-depth2019-04-29https://www.alacrita.com/case-studies/due-diligence-on-a-product-for-ards-in-covid-19-patients2023-01-20https://www.alacrita.com/about-alacrita-consulting2026-02-20https://www.alacrita.com/case-studies/due-diligence-valuation-preclinical-kinase-inhibitor2019-04-29https://www.alacrita.com/oncology-clinical-development-plans2024-09-24https://www.alacrita.com/contact-us-old2022-12-28https://www.alacrita.com/case-studies/interim-chief-medical-officer-for-fibrosis-company2024-02-01https://www.alacrita.com/case-studies/regulatory-affairs-bla-submission-support2019-04-29https://www.alacrita.com/case-studies/opportunity-analysis-of-an-antibody-cleaving-enzyme-in-oncology-autoimmune-diseases2024-02-19https://www.alacrita.com/case-studies/radionucleotide-imaging-due-diligence2019-04-29https://www.alacrita.com/case-studies/valuation-of-small-molecules-for-male-infertility2023-11-15https://www.alacrita.com/case-studies/clinical-cmc-regulatory-cmc-manufacturing-due-diligence2023-07-28https://www.alacrita.com/news/alacrita-proud-to-have-advised-menarini-group-on-its-strategic-alliance-with-oxford-biotherapeutics2019-04-29https://www.alacrita.com/news/alacrita-promotes-saadia-basharat-and-jess-hearn-messengerhttps://www.alacrita.com/hubfs/jess-saadia-promotion_v2.jpgjesssaadiapromotionv2jesssaadiapromotionv22023-10-05https://www.alacrita.com/blog/therapy-for-nash-cirrhosis-is-a-distant-hope2019-05-15https://www.alacrita.com/whitepapers/non-opioid-chronic-pain-market-analysis2025-09-30https://www.alacrita.com/case-studies/due-diligence-of-a-companys-commercial-forecasts2023-02-15https://www.alacrita.com/case-studies/board-observer-for-pe-investor2019-04-29https://www.alacrita.com/case-studies/accessible-biomarker-identification-technology2019-04-29https://www.alacrita.com/news/simon-turner-and-anthony-walker-attending-biotech-and-money-london2019-04-29https://www.alacrita.com/news/alacrita-establishes-powerful-regulatory-affairs-practice-to-serve-life-science-companies-and-investors2019-04-29https://www.alacrita.com/oncology-consulting2024-09-18https://www.alacrita.com/blog/risk-vs-uncertainty-biotech-due-diligencehttps://www.alacrita.com/hubfs/due-diligence-bg.jpgduediligencebgduediligencebg2026-02-11https://www.alacrita.com/case-studies/ibd-primary-market-research-opportunity-mapping2024-05-24https://www.alacrita.com/careers/experienced-management-consultants/https://www.alacrita.com/hubfs/alacrita_homepage.jpgalacritahomepagealacritahomepage2019-05-01https://www.alacrita.com/blog/misaligned-incentives-late-stage-drug-development-failureshttps://www.alacrita.com/hubfs/Li-Misaligned%20Incentives.jpgLiMisalignedIncentivesLiMisalignedIncentives2024-06-14https://www.alacrita.com/case-studies/providing-expert-regulatory-gene-therapy-manufacturing-advice2023-08-09https://www.alacrita.com/case-studies/indication-strategy-and-development-plan-for-a-microbiome-company2023-01-31https://www.alacrita.com/case-studies/biologics-gmp-facility-feasibility-study2019-04-29https://www.alacrita.com/case-studies/corporate-pitch-deck-and-partnering-deal-terms-for-european-biotech2025-01-20https://www.alacrita.com/case-studies/asset-scouting-for-psychoactive-drugs2023-11-17https://www.alacrita.com/case-studies/identiying-molecules-for-novel-formulation-technology2025-01-20https://www.alacrita.com/case-studies/due-diligence-on-a-new-medical-imaging-technology2019-10-14https://www.alacrita.com/blog/summer-2019-in-paris-nash-updatehttps://www.alacrita.com/hubfs/nash-collaborations.jpgnashcollaborationsnashcollaborations2019-09-20https://www.alacrita.com/case-studies/gap-analysis-pre-ind-meeting-preparation2023-07-21https://www.alacrita.com/pharma-companies2023-05-25https://www.alacrita.com/case-studies/managing-preclinical-programs2021-04-13https://www.alacrita.com/case-studies/designing-monitoring-anti-ngf-imaging-endpoints2019-04-29https://www.alacrita.com/case-studies/due-diligence-of-a-first-in-class-agent-for-spinocerebellar-ataxia2023-02-15https://www.alacrita.com/consultants/christine-mccarthy2019-04-19https://www.alacrita.com/case-studies/business-planning-valuation-cancer-immunotherapy-start2020-07-20https://www.alacrita.com/news/mark-wickham-appointed-as-partner-to-lead-alacritas-medtech-practice2019-04-29https://www.alacrita.com/consultants/michael-lombardohttps://www.alacrita.com/hubfs/Michael-Lombardo-new-3.jpgMichaelLombardonew3MichaelLombardonew32024-10-02https://www.alacrita.com/news/alacrita-expands-medical-due-diligence-team-appoints-christine-mccarthy2019-04-29https://www.alacrita.com/case-studies/gene-therapy-preclinical-development-support2024-05-24https://www.alacrita.com/case-studies/opportunity-mapping-for-hemojuvelin-antibody2024-02-19https://www.alacrita.com/case-studies/technical-commercial-due-diligence-of-biotech-holdings2023-08-08https://www.alacrita.com/whitepapers/drug-discovery-respect-the-waveshttps://www.alacrita.com/hubfs/due-diligence-bg.jpgduediligencebgduediligencebg2025-12-22https://www.alacrita.com/case-studies2026-02-17https://www.alacrita.com/drug-discovery-platform-consultinghttps://www.alacrita.com/hubfs/image-png-Aug-18-2022-03-15-35-66-PM.pngimagepngAug18202203153566PMimagepngAug18202203153566PMhttps://www.alacrita.com/hubfs/image-png-Aug-18-2022-03-15-24-33-PM.pngimagepngAug18202203152433PMimagepngAug18202203152433PM2022-08-23https://www.alacrita.com/case-studies/conducting-ip-due-diligence2019-04-29https://www.alacrita.com/whitepapers/pharmaceutical-probability-of-success2019-10-15https://www.alacrita.com/case-studies/pre-ind-meeting-support-for-repurposed-drug-for-stroke2024-02-09https://www.alacrita.com/accordion2022-07-20https://www.alacrita.com/case-studies/scouting-for-autoimmune-auto-inflammatory-assets2024-07-10https://www.alacrita.com/blog/rsv-vaccines-near-finish-linehttps://www.alacrita.com/hubfs/AdobeStock_471902144.jpegAdobeStock471902144AdobeStock4719021442022-11-03https://www.alacrita.com/whitepapers/europes-stellar-decade-of-prostate-cancer-innovationhttps://www.alacrita.com/hubfs/Imported_Blog_Media/Norway.pngNorwayNorwayhttps://www.alacrita.com/hubfs/Imported_Blog_Media/UK.pngUKUKhttps://www.alacrita.com/hubfs/Imported_Blog_Media/USA.pngUSAUSAhttps://www.alacrita.com/hubfs/Imported_Blog_Media/France.pngFranceFrance2019-04-29https://www.alacrita.com/case-studies/indication-opportunity-assessment-for-a-gene-therapy2023-01-31https://www.alacrita.com/blog/due-diligence-preparation-what-kills-deals2026-02-17https://www.alacrita.com/animal-health-consulting2024-09-23https://www.alacrita.com/blog/ema-solution-post-brexit-era2019-04-29https://www.alacrita.com/case-studies/supporting-medical-device-510k-submissions2024-02-19https://www.alacrita.com/case-studies/landscape-analysis-of-the-radiopharma-market2023-08-15https://www.alacrita.com/news/alacrita-opens-new-office-in-cambridge-uk2019-04-29https://www.alacrita.com/whitepapers/china-opportunities-for-biotech-firms2019-04-29https://www.alacrita.com/news/european-drug-development-a-masterclass2023-03-16https://www.alacrita.com/news/appoints-markus-peters-to-advise-clients-on-global-commercialization2019-04-29https://www.alacrita.com/case-studies/cancer-immunotherapy-combination-landscape-analysis2022-01-11https://www.alacrita.com/news/steven-quentzel-attending-dia-euromeeting-hamburg-germany2019-04-29https://www.alacrita.com/case-studies/biotech-consulting-case-study-womens-health-partnership-assessment2025-07-02https://www.alacrita.com/case-studies/developing-an-independent-market-report-for-a-cannabinoid-company-seeking-a-dual-listing2020-01-17https://www.alacrita.com/whitepapers/viewpoint-pharma-industry-myths2019-04-29https://www.alacrita.com/consultants/gary-mansfieldhttps://www.alacrita.com/hubfs/gary-mansfield.jpggarymansfieldgarymansfield2022-12-16https://www.alacrita.com/consultants/mark-philiphttps://www.alacrita.com/hubfs/mark-philip.jpgmarkphilipmarkphilip2020-07-20https://www.alacrita.com/case-studies/immunotherapy-strategy-radiotherapy-company2023-08-15https://www.alacrita.com/case-studies/vendor-due-diligence2019-07-26https://www.alacrita.com/case-studies/ma-search2023-02-02https://www.alacrita.com/blog/orkambi-uk-sound-and-fury2019-04-29https://www.alacrita.com/case-studies/valuation-of-phase-3-ready-alzheimers-drug2024-02-19https://www.alacrita.com/blog/pharma-valuations-when-to-use-incidence-prevalencehttps://www.alacrita.com/hubfs/prevalence.jpgprevalenceprevalencehttps://www.alacrita.com/hubfs/valuation-incidence-prevalence.jpgvaluationincidenceprevalencevaluationincidenceprevalence2019-09-20https://www.alacrita.com/case-studies/payer-research-and-pricing-assessment2019-04-29https://www.alacrita.com/case-studies/providing-due-diligence-novel-drug-formulation2019-04-29https://www.alacrita.com/case-studies/due-diligence-for-a-new-imaging-technology2019-08-02https://www.alacrita.com/case-studies/due-diligence-for-a-cdmo2023-01-31https://www.alacrita.com/case-studies/valuation-of-a-biotech-company-using-monte-carlo2023-01-31https://www.alacrita.com/case-studies/defining-a-clinical-strategy-in-oncology2022-08-18https://www.alacrita.com/case-studies/validating-two-potential-hormone-replacement-therapy-products-with-kols2022-06-21https://www.alacrita.com/case-studies/financial-hr-benchmarking-cancer-immunotherapy-company2020-07-20https://www.alacrita.com/case-studies/diagnostics-due-diligence2019-10-09https://www.alacrita.com/case-studies/commercial-planning-rare-oncology-disease2020-08-20https://www.alacrita.com/our-services/pharma-licensing-partnering-dealmaking2023-10-11https://www.alacrita.com/case-studies/providing-due-diligence-for-a-company-developing-rd-tools-using-pluripotent-stem-cells2019-08-05https://www.alacrita.com/case-studies/opportunity-analysis-of-phage-technology2019-10-16https://www.alacrita.com/case-studies/developing-a-target-product-profile-tpp-for-a-novel-gene-therapy2024-02-19https://www.alacrita.com/case-studies/providing-scientific-immunological-mechanism-action-due-diligence-big-pharma-client2024-02-19https://www.alacrita.com/case-studies/regulatory-support-in-obtaining-eu-orphan-drug-designation-for-a-gene-therapy2023-07-21https://www.alacrita.com/case-studies/axl-mertk-target-assessment-for-an-ai-driven-drug-discovery-company2025-01-20https://www.alacrita.com/case-studies/pediatric-oncology-due-diligence-biologic2025-05-05https://www.alacrita.com/case-studies/indication-strategy-for-reformulated-chemotherapy2023-07-20https://www.alacrita.com/case-studies/radiopharmaceutical-opportunity-mapping-market-landscaping2023-10-23https://www.alacrita.com/case-studies/providing-biotech-due-diligence-of-a-phase-lll-oncology-program2019-08-01https://www.alacrita.com/tech-transfer2024-12-02https://www.alacrita.com/news/alacrita-strengthens-european-team-to-advise-clients-on-clinical-development-strategy-planning-and-operations-appoints-keith-bragman-md-frcp2019-04-29https://www.alacrita.com/case-studies/due-diligence-on-a-novel-t-cell-therapy-and-discovery-platform2019-08-27https://www.alacrita.com/case-studies/interim-oncology-chief-medical-officer2022-08-17https://www.alacrita.com/case-studies/regulatory-strategy-and-preparation-for-pre-ind-meeting-with-the-fda2022-06-22https://www.alacrita.com/case-studies/cancer-clinical-development-strategy2019-04-29https://www.alacrita.com/case-studies/valuation-of-a-drug-discovery-company2021-04-30https://www.alacrita.com/biotech-case-study-database2025-10-16https://www.alacrita.com/blog/no-acceptable-surrogates-for-nash-cirrhosis2019-09-20https://www.alacrita.com/our-services/corporate-strategy-02019-07-26https://www.alacrita.com/case-studies/commercial-development-plan-for-a-mesenchymal-stem-cell-therapy-in-acute-gvhd2024-02-19https://www.alacrita.com/case-studies/economic-impact-research-institute2019-10-18https://www.alacrita.com/case-studies/supporting-bla-submissions2022-08-15https://www.alacrita.com/case-studies/regulatory-plan-for-a-biotech-with-proprietary-nanotechnology2019-08-22https://www.alacrita.com/case-studies/pipeline-strategy-for-gene-therapy-company2024-02-19https://www.alacrita.com/case-studies/due-diligence-on-new-biosensor-technology2024-02-19https://www.alacrita.com/case-studies/intellectual-property2019-04-29https://www.alacrita.com/case-studies/ip-portfolio-review-for-uk-charity2019-10-21https://www.alacrita.com/blog/is-rapid-reversal-of-liver-fibrosis-possible2019-04-30https://www.alacrita.com/case-studies/pre-dd-on-re-purposed-ophthalmology-product2023-11-16https://www.alacrita.com/case-studies/acquisition-licensing-landscape-for-technologies-in-fertility-womens-health2019-08-23https://www.alacrita.com/case-studies/opportunity-mapping-of-a-potential-first-line-therapeutic-for-bladder-cancer2023-02-15https://www.alacrita.com/case-studies/scouting-for-in-licensing-opportunities-in-fibrosis2024-02-01https://www.alacrita.com/case-studies/clinical-and-regulatory-due-diligence-of-an-asset-targeting-pre-term-birth-complications2023-11-29https://www.alacrita.com/blog/could-covid-19-be-a-catalyst-for-virtualizing-clinical-trialshttps://www.alacrita.com/hubfs/telehealth.jpgtelehealthtelehealth2020-10-27https://www.alacrita.com/whitepapers/pharma-licensing-trends-and-wishlisthttps://www.alacrita.com/hubfs/flashlight%20copy.jpgflashlightcopyflashlightcopyhttps://www.alacrita.com/hubfs/percentage-interest-by-therapeutic-area.pngpercentageinterestbytherapeuticareapercentageinterestbytherapeuticareahttps://www.alacrita.com/hubfs/pharma-partnering-interests-1.pngpharmapartneringinterests1pharmapartneringinterests12021-08-04https://www.alacrita.com/life-science-consultinghttps://www.alacrita.com/hubfs/Due%20Diligence%20-%20LI.jpgDueDiligenceLIDueDiligenceLIhttps://www.alacrita.com/hubfs/due-diligence-bg.jpgduediligencebgduediligencebg2024-06-28https://www.alacrita.com/blog/nash-surprises-and-interpretation-of-clinical-trialshttps://www.alacrita.com/hubfs/Imported_Blog_Media/figure_1.pngfigure1figure1https://www.alacrita.com/hubfs/Imported_Blog_Media/figure_2.pngfigure2figure2https://www.alacrita.com/hubfs/Imported_Blog_Media/figure_3-1.pngfigure31figure312019-04-30https://www.alacrita.com/case-studies/scouting-in-licensing-targets-in-inflammation-and-fibrosis2024-02-09https://www.alacrita.com/case-studies/indication-triaging-for-aav-based-gene-therapies2023-11-17https://www.alacrita.com/news/alacrita-establishes-u-s-headquarters-in-boston-area2019-04-29https://www.alacrita.com/case-studies/small-molecule-assets2024-02-19https://www.alacrita.com/cort-heplerhttps://www.alacrita.com/hubfs/Cort-HeadShot-BW.jpgCortHeadShotBWCortHeadShotBW2026-02-16https://www.alacrita.com/case-studies/opportunity-analysis-blood-products2019-04-29https://www.alacrita.com/case-studies/providing-due-diligence-in-inflammation-and-fibrosis-area2024-02-19https://www.alacrita.com/case-studies/scouting-medtech-ma-opportunities2019-10-03https://www.alacrita.com/whitepapers/mitigating-out-sourcing-riskhttps://www.alacrita.com/hubfs/Imported_Blog_Media/Picture11-300x208.jpgPicture11300x208Picture11300x208https://www.alacrita.com/hubfs/Imported_Blog_Media/Picture3-300x207.jpgPicture3300x207Picture3300x207https://www.alacrita.com/hubfs/Imported_Blog_Media/Picture2-300x209.jpgPicture2300x209Picture2300x2092019-08-14https://www.alacrita.com/case-studies/valuation-of-a-portfolio-of-therapeutics-for-an-investment-firm2023-11-15https://www.alacrita.com/whitepapers/combining-cancer-immunotherapy-and-antifibrotics-to-treat-cold-tumors2025-01-06https://www.alacrita.com/case-studies/validating-the-opportunity-for-a-novel-anticoagulant-with-kol-research2024-01-12https://www.alacrita.com/blog/beyond-rnpv-valuations-pharma-assetshttps://www.alacrita.com/hubfs/abstract-chart.jpgabstractchartabstractcharthttps://www.alacrita.com/hubfs/image-png-Feb-22-2023-10-48-46-0257-PM.pngimagepngFeb2220231048460257PMimagepngFeb2220231048460257PMhttps://www.alacrita.com/hubfs/pharma-asset-sellability.pngpharmaassetsellabilitypharmaassetsellability2023-02-24https://www.alacrita.com/whitepapers/compounding-pharmacies-drug-development-implications2026-02-10https://www.alacrita.com/early-stage-biotech-valuations2024-09-19https://www.alacrita.com/case-studies/applying-to-early-access-to-medicines-eams-at-the-mh2023-08-15https://www.alacrita.com/case-studies/valuation-of-a-cancer-therapy-for-licensing-deal2019-08-28https://www.alacrita.com/blog/european-biotech-gaining-weight-learning-patience2019-04-29https://www.alacrita.com/case-studies/providing-due-diligence-neurology2019-04-29https://www.alacrita.com/case-studies/market-opportunity-for-colistin-potentiators2019-10-28https://www.alacrita.com/case-studies/gap-analysis-for-a-cta-submission-in-the-uk2024-02-19https://www.alacrita.com/insights2026-01-19https://www.alacrita.com/digestive-gi-drug-development-consultantshttps://www.alacrita.com/hubfs/image-png-May-24-2024-03-32-27-4629-PM.pngimagepngMay2420240332274629PMimagepngMay2420240332274629PMhttps://www.alacrita.com/hubfs/image-png-May-24-2024-03-32-21-2720-PM.pngimagepngMay2420240332212720PMimagepngMay2420240332212720PM2024-05-24https://www.alacrita.com/blog/whats-difference-biotech-pharma2022-07-03https://www.alacrita.com/blog/wisdom-henri-termeer-1946-20172019-04-29https://www.alacrita.com/blog/is-gileads-selonsetib-for-nash-deadhttps://www.alacrita.com/hubfs/Imported_Blog_Media/NASH-CRN-Fibrosis-Stage.pngNASHCRNFibrosisStageNASHCRNFibrosisStage2019-04-30https://www.alacrita.com/blog/nash-bubble2022-11-02https://www.alacrita.com/case-studies/new-in-licensing-opportunities-in-inflammation2019-04-29https://www.alacrita.com/case-studies/rare-disease-landscape-and-acquisition-screening2024-01-12https://www.alacrita.com/case-studies/providing-search-assessment-support-oncology-projects2019-04-29https://www.alacrita.com/case-studies/supporting-biotech-companys-pharma-partnerships2019-04-29https://www.alacrita.com/case-studies/regulatory-assessment-of-a-generic-anti-diabetic-peptide-drug2022-08-18https://www.alacrita.com/case-studies/independent-review-clinical-trial-data2019-10-09https://www.alacrita.com/biotech-pharma-consulting-tech-transfer-offices2024-12-02https://www.alacrita.com/case-studies/search-acquisition-targets-usa2019-10-22https://www.alacrita.com/whitepapers/anti-obesity-drugs-development-pipeline-market-analysishttps://www.alacrita.com/hubfs/image-png-Jul-18-2025-07-12-29-7991-PM.pngimagepngJul1820250712297991PMimagepngJul1820250712297991PMhttps://www.alacrita.com/hubfs/image-png-Jul-18-2025-05-40-23-1811-PM.pngimagepngJul1820250540231811PMimagepngJul1820250540231811PMhttps://www.alacrita.com/hubfs/Obesity%20-%20Pill2.jpgObesityPill2ObesityPill2https://www.alacrita.com/hubfs/image-png-Jul-18-2025-05-41-43-9286-PM.pngimagepngJul1820250541439286PMimagepngJul1820250541439286PMhttps://www.alacrita.com/hubfs/image-png-Jul-18-2025-05-40-59-2885-PM.pngimagepngJul1820250540592885PMimagepngJul1820250540592885PM2025-08-25https://www.alacrita.com/news/susanta-sarkar-attending-world-molecular-imaging-congress-in-new-york2019-04-29https://www.alacrita.com/news/alacrita-and-inc-research-hosting-thought-leadership-luncheon-on-thursday-november-32019-04-29https://www.alacrita.com/case-studies/supporting-a-cta-submission-for-the-oral-form-of-an-approved-biologic-drug2022-08-18https://www.alacrita.com/whitepapers/cellular-immunotherapy-challenges-and-potential-solutionshttps://www.alacrita.com/hubfs/alacrita-biotech-consulting-immunotherapy.jpgalacritabiotechconsultingimmunotherapyalacritabiotechconsultingimmunotherapy2021-02-01https://www.alacrita.com/case-studies/supporting-chief-medical-officer2019-04-29https://www.alacrita.com/case-studies/due-diligence-on-a-reverse-merger-candidate-with-pipeline-of-ind-ready-compounds2022-08-17https://www.alacrita.com/blog/emerging-ophthalmology-therapies-2025https://www.alacrita.com/hubfs/Eyes%20Wide%20Open%20v2.jpgEyesWideOpenv2EyesWideOpenv22025-06-03https://www.alacrita.com/case-studies/documentation-gap-analysis-in-preparation-for-fda-scientific-advice-meeting2019-08-28https://www.alacrita.com/case-studies/clinical-strategy-medical-oversight-and-clinical-due-diligence2020-08-20https://www.alacrita.com/our-services/pharma-strategy-commercialization2024-02-29https://www.alacrita.com/case-studies/valuing-cancer-immunotherapy-asset2020-07-20https://www.alacrita.com/case-studies/womens-health-pre-due-diligence-mid-cap-pharma2025-05-30https://www.alacrita.com/microbiome-drug-development-consultants2024-02-09https://www.alacrita.com/case-studies/feasibility-study-ophthalmic-therapies2019-04-29https://www.alacrita.com/our-services/pharmaceutical-intellectual-propertyhttps://www.alacrita.com/hubfs/due-diligence-bg-1.jpgduediligencebg1duediligencebg12024-02-23https://www.alacrita.com/case-studies/pre-due-diligence-of-two-early-stage-assets-a-nano-adc-a-small-molecule2022-08-09https://www.alacrita.com/case-studies/eu-payer-research-for-novel-mab-treatment-for-hidradenitis-suppurativa2022-08-10https://www.alacrita.com/case-studies/regulatory-analysis-of-rejected-marketing-authorization-response-strategy2023-11-17https://www.alacrita.com/whitepapers/cell-therapy-financing-beyond-car-thttps://www.alacrita.com/hubfs/cell-therapy-vials.jpgcelltherapyvialscelltherapyvials2026-02-17https://www.alacrita.com/our-services/clinical-development2026-01-15https://www.alacrita.com/news/commercialisation-of-cellular-immunotherapies-for-cancer2019-04-29https://www.alacrita.com/case-studies/commercial-supply-chain-for-us-launch-of-a-blood-cancer-drug2024-02-19https://www.alacrita.com/case-studies/dd-for-a-biotech-developing-an-ai-driven-drug-discovery-platform2024-02-19https://www.alacrita.com/whitepapers/european-payer-advisory-boards2019-04-29https://www.alacrita.com/case-studies/investor-due-diligence-for-a-biotherapeutic-product2024-01-12https://www.alacrita.com/whitepapers/are-we-all-biotech-now2019-04-29https://www.alacrita.com/case-studies/microbiome-opportunity-mapping2024-01-23https://www.alacrita.com/case-studies/independent-strategic-review-of-a-target-company-developing-a-protein-for-multiple-immune-indications2025-01-03https://www.alacrita.com/case-studies/pharmaceutical-regulatory-affairs-case-studies2022-07-05https://www.alacrita.com/case-studies/due-diligence-small-molecule-arising-phenotypic-screen2019-04-29https://www.alacrita.com/case-studies/eu-payer-research-to-inform-phase-3-design2019-04-29https://www.alacrita.com/blog/covid-19-a-catalyst-for-anti-infective-investinghttps://www.alacrita.com/hubfs/shield-virus%20copy.jpgshieldviruscopyshieldviruscopy2024-05-29https://www.alacrita.com/case-studies/due-diligence-of-a-microbiome-company-biotech-consulting2022-06-30https://www.alacrita.com/blog/madrigals-and-vikings-nash-drugs-whos-best-in-class2019-04-30https://www.alacrita.com/case-studies/ad-hoc-cmc-and-regulatory-support-aav-in-vivo-trans-differentiation2022-08-16https://www.alacrita.com/case-studies/clinical-and-regulatory-support-for-respiratory-delivery-specialist2024-03-19https://www.alacrita.com/case-studies/supporting-tto-biotech-research2024-05-16https://www.alacrita.com/whitepapers/pharma-and-biotech-valuations-divergent-perspectiveshttps://www.alacrita.com/hubfs/Imported_Blog_Media/Figure-2-.jpgFigure2Figure2https://www.alacrita.com/hubfs/Imported_Blog_Media/Table-1.jpgTable1Table1https://www.alacrita.com/hubfs/Imported_Blog_Media/Figure-1-.jpgFigure1Figure12023-02-22https://www.alacrita.com/case-studies/technical-feasibility-ranking-of-gene-therapies-for-cns-diseases2025-01-20https://www.alacrita.com/case-studies/us-market-access-plan-for-antibody-launch2023-07-21https://www.alacrita.com/case-studies/primary-market-research-and-patient-segmentation-mapping-in-myelofibrosis2024-02-19https://www.alacrita.com/case-studies/landscape-assessment-of-novel-pain-targets-for-rd-prioritization2025-03-25https://www.alacrita.com/blog2026-01-19https://www.alacrita.com/case-studies/asset-scouting-for-novel-injectable-formulations-for-large-pharma2025-01-03https://www.alacrita.com/case-studies/roadmap-for-commercial-data-infrastructure-build-to-support-rare-disease-drug-launch2019-11-07https://www.alacrita.com/case-studies/rd-pipeline-planning-for-gene-therapy-company2022-08-16https://www.alacrita.com/case-studies/consulting-monoclonal-antibodies-treat-bacterial-infections2019-04-29https://www.alacrita.com/case-studies/antibody-consultants-bacterial-infectionshttps://www.alacrita.com/hubfs/alacrita_how_we_can_help_therapeutic_area_strategy.jpgalacritahowwecanhelptherapeuticareastrategyalacritahowwecanhelptherapeuticareastrategy2019-04-29https://www.alacrita.com/case-studies/due-diligence-on-generic-therapeutic2019-04-29https://www.alacrita.com/case-studies/scouting-in-licensing-opportunities-for-a-mid-size-pharma-company2023-08-18https://www.alacrita.com/case-studies/preparing-a-eu-paediatric-investigators-plan2023-11-14https://www.alacrita.com/case-studies/development-plan-for-novel-small-molecule-for-prostate-cancer2022-08-17https://www.alacrita.com/case-studies/interim-cmo-for-an-innovative-biopharma-company2019-10-18https://www.alacrita.com/peptide-protein-drug-consultinghttps://www.alacrita.com/hubfs/image-png-Aug-17-2022-03-04-00-84-PM.pngimagepngAug17202203040084PMimagepngAug17202203040084PMhttps://www.alacrita.com/hubfs/image-png-Aug-17-2022-03-04-27-25-PM.pngimagepngAug17202203042725PMimagepngAug17202203042725PM2025-01-27https://www.alacrita.com/blog/targeted-radiotherapy-cancer-treatment2022-03-29https://www.alacrita.com/whitepapers/whitepapers/is-manufacturing-just-bad-news2019-04-29https://www.alacrita.com/case-studies/opportunity-map-for-imaging-printing-technology2019-10-14https://www.alacrita.com/case-studies/strategic-analysis-of-preclinical-data-for-a-lipid-combination-treatment2022-08-17https://www.alacrita.com/privacy-policy2022-10-06https://www.alacrita.com/consultants/tatiana-gouldhttps://www.alacrita.com/hubfs/3work.jpg3work3work2023-09-13https://www.alacrita.com/case-studies/strategic-audit-and-turn-around-strategy-for-global-animal-health-company2024-09-24https://www.alacrita.com/case-studies/advising-educational-institutions-technology-transfer2024-05-16https://www.alacrita.com/case-studies/pharma-commercial-supply-chain-consulting2021-08-26https://www.alacrita.com/small-molecule-drug-consultinghttps://www.alacrita.com/hubfs/image-png-Aug-17-2022-03-04-00-84-PM.pngimagepngAug17202203040084PMimagepngAug17202203040084PMhttps://www.alacrita.com/hubfs/image-png-Aug-17-2022-03-04-27-25-PM.pngimagepngAug17202203042725PMimagepngAug17202203042725PM2022-08-25https://www.alacrita.com/whitepapers/pharmaceutical-patent-term-extension-an-overview2019-10-16https://www.alacrita.com/case-studies/sales-forecast-in-metastatic-colorectal-and-gastric-cancer2023-02-15https://www.alacrita.com/radiopharmaceuticals2024-09-12https://www.alacrita.com/whitepapers/the-ipsc-clinical-landscape-a-bright-future-aheadhttps://www.alacrita.com/hubfs/green-cell-division.jpeggreencelldivisiongreencelldivisionhttps://www.alacrita.com/hubfs/iPSC-organ-cell-system-modeling.jpgiPSCorgancellsystemmodelingiPSCorgancellsystemmodeling2023-11-01https://www.alacrita.com/case-studies/investor-pitch-deck-for-biotech-developing-non-opioid-analgesic2023-07-21https://www.alacrita.com/blog/what-happens-to-pharma-valuations-as-interest-rates-risehttps://www.alacrita.com/hubfs/Sensitivity%20of%20rNPV.jpgSensitivityofrNPVSensitivityofrNPVhttps://www.alacrita.com/hubfs/3-month%20treasury%20copy.jpg3monthtreasurycopy3monthtreasurycopyhttps://www.alacrita.com/hubfs/stock-chart-blue.jpgstockchartbluestockchartblue2022-09-20https://www.alacrita.com/blog/why-every-biotech-needs-a-scouting-functionhttps://www.alacrita.com/hubfs/Imported_Blog_Media/valuation-bump-in-licensing-deals.jpgvaluationbumpinlicensingdealsvaluationbumpinlicensingdealshttps://www.alacrita.com/hubfs/Imported_Blog_Media/I-O-Landscape-2.jpgIOLandscape2IOLandscape22022-07-19https://www.alacrita.com/blog/mrna-vaccines-ready-for-prime-time2019-04-29https://www.alacrita.com/blog/how-fractional-cmos-propel-biotech-successhttps://www.alacrita.com/hubfs/alacrita_homepage.jpgalacritahomepagealacritahomepage2024-11-19https://www.alacrita.com/case-studies/oligo-technology-applications-mapping2023-11-01https://www.alacrita.com/case-studies/eu-us-and-japan-payer-research-for-a-novel-immunotherapy-in-advanced-rcc2023-07-21https://www.alacrita.com/blog/britain-crashes-out-of-favor-with-us-pharmaceutical-executiveshttps://www.alacrita.com/hubfs/Imported_Blog_Media/Alacrita-US-Pharma-Exec-Opinions-Brexit-Infographic.jpgAlacritaUSPharmaExecOpinionsBrexitInfographicAlacritaUSPharmaExecOpinionsBrexitInfographic2019-04-30https://www.alacrita.com/case-studies/helping-oncology-company-preclinical-project-seek-finance-potential-acquisition2021-04-29https://www.alacrita.com/expert-witness2024-11-21https://www.alacrita.com/whitepapers/fda-approvals-provide-reason-for-cheer2019-04-29https://www.alacrita.com/blog/china-drug-approval-reforms-speed-regulatory-competition2025-11-19https://www.alacrita.com/consulting-resources2023-07-29https://www.alacrita.com/blog/were-all-china-now2025-11-19https://www.alacrita.com/case-studies/benchmarking-products-diagnostics-market2019-04-29https://www.alacrita.com/news/steven-quentzel-attending-eahad-sweden2019-04-29https://www.alacrita.com/biotech-investor-relations2025-05-20https://www.alacrita.com/blog/monetizing-the-microbiome2019-10-18https://www.alacrita.com/case-studies/triage-dd-of-short-bowel-syndrome-assets2024-02-19https://www.alacrita.com/blog/nash-cirrhosis-space-poised-to-heat-uphttps://www.alacrita.com/hubfs/Imported_Blog_Media/nash-cirrhosis-clinical-trials-by-patient-segment.jpgnashcirrhosisclinicaltrialsbypatientsegmentnashcirrhosisclinicaltrialsbypatientsegmenthttps://www.alacrita.com/hubfs/Imported_Blog_Media/Estimated-Data-Milestones-for-NASH-Cirrhosis-Trials.jpgEstimatedDataMilestonesforNASHCirrhosisTrialsEstimatedDataMilestonesforNASHCirrhosisTrials2019-04-30https://www.alacrita.com/blog/ema-policy-0070-transparencyhttps://www.alacrita.com/hubfs/LI%20Post%20-%20Unconscious%20Bias.jpgLIPostUnconsciousBiasLIPostUnconsciousBias2024-10-17https://www.alacrita.com/case-studies/due-diligence-of-plasma-protein-manufacturer2022-08-18https://www.alacrita.com/news/rob-johnson-attends-cancer-advance-boston2019-04-29https://www.alacrita.com/case-studies/valuation-modelling-front-loaded-vs-risk-sharing-deal-drug-discovery-collaboration2019-04-29https://www.alacrita.com/case-studies/due-diligence-of-first-in-class-monoclonal-antibody-candidate-drug2024-02-01https://www.alacrita.com/blog/pharma-defying-gravity-how-much-longer2019-04-29https://www.alacrita.com/biotech-pharma-consulting2024-03-06https://www.alacrita.com/whitepapers/due-diligence-the-pinnacle-of-expertise-based-consultinghttps://www.alacrita.com/hubfs/yellow_button_out.pngyellowbuttonoutyellowbuttonouthttps://www.alacrita.com/hubfs/expert-network-background.jpgexpertnetworkbackgroundexpertnetworkbackgroundhttps://www.alacrita.com/hubfs/alacrita-pharma-due-diligence-3.pngalacritapharmaduediligence3alacritapharmaduediligence32026-02-12https://www.alacrita.com/blog/the-financing-dose-response-curve-how-much-is-too-much-for-biotechhttps://www.alacrita.com/hubfs/image-png-Feb-13-2024-12-40-10-2607-PM.pngimagepngFeb1320241240102607PMimagepngFeb1320241240102607PM2024-03-05https://www.alacrita.com/blog/industry-strategies-for-nash-combination-therapies2019-04-30https://www.alacrita.com/case-studies/presenting-technology-clinical-programs-at-ash-sabcs2023-07-21https://www.alacrita.com/case-studies/nash-drug-development-strategy2019-04-29https://www.alacrita.com/biotech-enterprise-development2026-02-17https://www.alacrita.com/our-services/pharmaceutical-launch-planning2023-04-27https://www.alacrita.com/case-studies/cta-submission-support-for-a-monoclonal-antibody-in-primary-sclerosing-cholangitis2022-08-10https://www.alacrita.com/case-studies/cancer-vaccines2023-08-15https://www.alacrita.com/case-studies/medical-oversight-support-for-oncology-clinical-trials2019-10-14https://www.alacrita.com/case-studies/pharmaceutical-licensing-input-into-term-sheet-negotiation2022-09-26https://www.alacrita.com/case-studies/radiopharmaceuticals2019-04-29https://www.alacrita.com/news/david-glover-joins-the-alacrita-team2019-04-29https://www.alacrita.com/blog/moving-beyond-cancer-car-t-therapy-takes-on-autoimmune-diseasehttps://www.alacrita.com/hubfs/AdobeStock_202780589.jpegAdobeStock202780589AdobeStock2027805892021-02-12https://www.alacrita.com/blog/how-to-start-a-biotech-company2022-02-17https://www.alacrita.com/blog/pharma-partnering-successhttps://www.alacrita.com/hubfs/antibody.jpgantibodyantibodyhttps://www.alacrita.com/hubfs/Screenshot%202023-09-06%20at%2010.09.47%20AM.pngScreenshot20230906at100947AMScreenshot20230906at100947AMhttps://www.alacrita.com/hubfs/Screenshot%202023-09-06%20at%2010.09.41%20AM-1.pngScreenshot20230906at100941AM1Screenshot20230906at100941AM12023-11-06https://www.alacrita.com/case-studies/mapping-an-oncology-project-opportunity-to-support-fundraising2019-10-09https://www.alacrita.com/case-studies/due-diligence-on-a-computational-chemistry-software-for-a-private-equity-firm2024-01-12https://www.alacrita.com/regulatory-approval-consulting2024-07-23https://www.alacrita.com/case-studies/cell-and-gene-therapy-regulatory-support2022-08-15https://www.alacrita.com/case-studies/valuation-of-epp-drug-to-support-in-licensing-negotiation2022-06-21https://www.alacrita.com/blog/best-prioritize-ip-portfolio-universities-charities-research-funding-bodies2019-04-29https://www.alacrita.com/whitepapers/an-analysis-of-the-cellular-immunotherapy-landscape-for-cancerhttps://www.alacrita.com/hubfs/Figure-1.pngFigure1Figure1https://www.alacrita.com/hubfs/Figure-3-1.pngFigure31Figure31https://www.alacrita.com/hubfs/AdobeStock_202633698.jpegAdobeStock202633698AdobeStock202633698https://www.alacrita.com/hubfs/Figure-9-1.pngFigure91Figure91https://www.alacrita.com/hubfs/Figure-8-1.pngFigure81Figure81https://www.alacrita.com/hubfs/Figure-2-1.pngFigure21Figure21https://www.alacrita.com/hubfs/Figure-5.pngFigure5Figure5https://www.alacrita.com/hubfs/Figure-7-1.pngFigure71Figure71https://www.alacrita.com/hubfs/Figure-6-2.pngFigure62Figure62https://www.alacrita.com/hubfs/Figure-4.pngFigure4Figure42020-09-03https://www.alacrita.com/case-studies/clinical-protocol-review-in-oncology2024-02-19https://www.alacrita.com/blog/disease-indications-for-anti-fibrotic-drugshttps://www.alacrita.com/hubfs/Anti-Fibrotic%20Drug%20Disease%20Indication.jpgAntiFibroticDrugDiseaseIndicationAntiFibroticDrugDiseaseIndicationhttps://www.alacrita.com/hubfs/fibrosis-disease-indications-graphic.pngfibrosisdiseaseindicationsgraphicfibrosisdiseaseindicationsgraphic2024-04-17https://www.alacrita.com/case-studies/jp-morgan-prep-for-ai-biotech2023-02-02https://www.alacrita.com/news/whitepaper-medtech-how-to-succeed-in-europe2019-04-29https://www.alacrita.com/case-studies/assessing-aav-gene-therapy-ophthalmic-indication2019-10-08https://www.alacrita.com/preclinical-drug-development2026-01-13https://www.alacrita.com/news/alacrita-expands-investor-support-serviceshttps://www.alacrita.com/hubfs/lucas-investor-advisory-post.pnglucasinvestoradvisorypostlucasinvestoradvisorypost2025-05-20https://www.alacrita.com/news/saadia-basharat-attending-praxisunico-stratford-upon-avon-uk2019-04-29https://www.alacrita.com/life-science-consulting-02024-12-30https://www.alacrita.com/case-studies/providing-due-diligence-support-clinical-stage-type-1-diabetes-immunotherapy-project2020-07-20https://www.alacrita.com/case-studies/assessing-the-bd-landscape-for-in-licensing-acquisition-deals2024-02-19https://www.alacrita.com/case-studies/key-opinion-leader-payer-research-metastatic-breast-cancer2019-10-16https://www.alacrita.com/case-studies/commercial-development-plan-for-a-car-t-therapy-in-pancreatic-ductal-adenocarcinoma2019-10-24https://www.alacrita.com/case-studies/strategic-operational-support-start-oncology-company2019-04-29https://www.alacrita.com/case-studies/valuation-and-deal-support2019-04-29https://www.alacrita.com/case-studies/matching-sellers-buyers-wound-care-product2019-04-29https://www.alacrita.com/case-studies/indication-selection-assessment-for-clinical-stage-oncology-small-molecule2022-08-17https://www.alacrita.com/case-studies/due-diligence-of-a-biotech-with-a-novel-single-chain-antibody-platform2022-08-10https://www.alacrita.com/case-studies/search-assessment-stem-cell-therapies2019-10-07https://www.alacrita.com/our-services/target-product-profile-guidance2024-09-19https://www.alacrita.com/case-studies/providing-technical-transfer-validation-commercial-manufacturing-process-tablet-formulations2019-04-29https://www.alacrita.com/case-studies/valuation-of-a-radiolabelled-peptide-for-diagnosis-of-pulmonary-diseases2024-02-19https://www.alacrita.com/life-science-investor-support2025-09-21https://www.alacrita.com/our-services/life-science-business-consulting-old2019-09-06https://www.alacrita.com/blog/routes-to-european-commercialisation-in-europehttps://www.alacrita.com/hubfs/Imported_Blog_Media/Figure-4-Key-stages-of-planning-to-ensure-successful-strategy-implementation.jpgFigure4KeystagesofplanningtoensuresuccessfulstrategyimplementationFigure4Keystagesofplanningtoensuresuccessfulstrategyimplementationhttps://www.alacrita.com/hubfs/Imported_Blog_Media/Figure-3-The-Global-Access-to-Healthcare-Index-Criteria-and-Top-10-Performing-Countries.jpgFigure3TheGlobalAccesstoHealthcareIndexCriteriaandTop10PerformingCountriesFigure3TheGlobalAccesstoHealthcareIndexCriteriaandTop10PerformingCountrieshttps://www.alacrita.com/hubfs/Imported_Blog_Media/Figure-1-Breakdown-of-Worldwide-Pharmaceutical-Market.jpgFigure1BreakdownofWorldwidePharmaceuticalMarketFigure1BreakdownofWorldwidePharmaceuticalMarkethttps://www.alacrita.com/hubfs/Imported_Blog_Media/Figure-2-Reference-Drug-Pricing-across-European-Countries.jpgFigure2ReferenceDrugPricingacrossEuropeanCountriesFigure2ReferenceDrugPricingacrossEuropeanCountries2019-04-30https://www.alacrita.com/consultants/anthony-walkerhttps://www.alacrita.com/hubfs/anthony-walker-managing-partner.jpganthonywalkermanagingpartneranthonywalkermanagingpartner2024-04-02https://www.alacrita.com/alacrita-expert-network-02021-06-23https://www.alacrita.com/whitepapers/ai-in-small-molecule-drug-discoveryhttps://www.alacrita.com/hubfs/Ai-schematic.pngAischematicAischematichttps://www.alacrita.com/hubfs/AI-drug-discovery-graph.jpgAIdrugdiscoverygraphAIdrugdiscoverygraphhttps://www.alacrita.com/hubfs/AI-Summary.pngAISummaryAISummaryhttps://www.alacrita.com/hubfs/AI%20post%20image%20-%20no%20text.jpgAIpostimagenotextAIpostimagenotext2024-01-11https://www.alacrita.com/case-studies/licensing-due-diligence-respiratory-drug2019-04-29https://www.alacrita.com/case-studies/indication-prioritization-for-oligonucleotide-based-therapeutics2023-11-29https://www.alacrita.com/case-studies/scouting-for-metabolic-disease-assets-to-license2024-05-13https://www.alacrita.com/whitepapers/next-generation-chemotherapyhttps://www.alacrita.com/hubfs/rd-image.jpgrdimagerdimage2023-06-06https://www.alacrita.com/news/alacrita-appoints-peter-traber-to-lead-consulting-on-antifibrotic-drug-development2019-04-29https://www.alacrita.com/case-studies/assessing-antibody-targets-ip-risk2022-08-15https://www.alacrita.com/whitepapers/european-medtech-how-to-succeed-in-europe2019-04-29https://www.alacrita.com/case-studies/expert-advice-dxa-clinical-trials2019-04-29https://www.alacrita.comhttps://www.alacrita.com/hubfs/gray-open-quotes.pnggrayopenquotesgrayopenquoteshttps://www.alacrita.com/hubfs/Ink-bg-black-overlay.jpgInkbgblackoverlayInkbgblackoverlay2025-12-02https://www.alacrita.com/whitepapers/a-patient-reported-outcomes-analysis-of-lanreotide-in-the-treatment-of-nets-patients-with-carcinoid-syndromehttps://www.alacrita.com/hubfs/patient-outcomes-cumulative-responses.jpgpatientoutcomescumulativeresponsespatientoutcomescumulativeresponseshttps://www.alacrita.com/hubfs/patient-outcomes-table-1.jpgpatientoutcomestable1patientoutcomestable1https://www.alacrita.com/hubfs/patient-outcomes-table-2-1.jpgpatientoutcomestable21patientoutcomestable212019-11-11https://www.alacrita.com/consultants/chris-owens2024-05-24https://www.alacrita.com/case-studies/alzheimers-due-diligence-for-strategic-investor2024-02-19https://www.alacrita.com/endocrine-metabolic-drug-development-consultantshttps://www.alacrita.com/hubfs/image-png-May-13-2024-07-11-25-4278-PM.pngimagepngMay1320240711254278PMimagepngMay1320240711254278PMhttps://www.alacrita.com/hubfs/image-png-May-13-2024-07-11-30-7775-PM.pngimagepngMay1320240711307775PMimagepngMay1320240711307775PM2024-05-13https://www.alacrita.com/case-studies/supporting-radiopharmaceutical-rd2023-10-23https://www.alacrita.com/case-studies/pre-due-diligence-assessment-of-first-in-class-allergy-therapeutic2025-08-06https://www.alacrita.com/blog/targeted-protein-degradation-a-new-pharmacology-paradigmhttps://www.alacrita.com/hubfs/protac-drugs-in-development-by-stage.jpgprotacdrugsindevelopmentbystageprotacdrugsindevelopmentbystagehttps://www.alacrita.com/hubfs/protein-conceptual.jpgproteinconceptualproteinconceptualhttps://www.alacrita.com/hubfs/protac-drugs-in-development.jpgprotacdrugsindevelopmentprotacdrugsindevelopmenthttps://www.alacrita.com/hubfs/protac-drugs-in-development-by-indication.jpgprotacdrugsindevelopmentbyindicationprotacdrugsindevelopmentbyindication2022-10-20https://www.alacrita.com/case-studies/analysis-of-third-party-valuation-for-merger2023-01-31https://www.alacrita.com/blog/maybe-they-should-start-calling-it-decelerated-approvalhttps://www.alacrita.com/hubfs/bike-parachute.jpgbikeparachutebikeparachute2023-04-20https://www.alacrita.com/our-services/functional-roleshttps://www.alacrita.com/hubfs/alacrita_how_we_can_help_therapeutic_area_strategy.jpgalacritahowwecanhelptherapeuticareastrategyalacritahowwecanhelptherapeuticareastrategy2019-08-15https://www.alacrita.com/news/susanta-sarkar-is-presenting-at-the-pharma-imaging-network-for-therapeutics-and-diagnostics-meeting2019-04-29https://www.alacrita.com/case-studies/assessment-of-tlr-immunomodulators-in-oncology-and-hiv2021-06-22https://www.alacrita.com/case-studies/consulting-clinical-strategies-novel-cancer-immunotherapy2023-08-15https://www.alacrita.com/news/alacrita-builds-sulting-practice2019-04-29https://www.alacrita.com/case-studies/providing-expertise-oncology-scientific-advisory-board2019-04-29https://www.alacrita.com/news/alacrita-stengthens-cambridge-ma-team-appoints-william-slichenmyer-as-associate-partner2019-04-29https://www.alacrita.com/case-studies/opportunity-mapping-indication-strategy-for-company-developing-exosome-based-therapies2022-08-16https://www.alacrita.com/case-studies/competitive-and-market-landscape-for-car-t-cell-therapy2023-08-18https://www.alacrita.com/case-studies/providing-reality-checks-on-commercial-opportunities2019-08-05https://www.alacrita.com/news/alacrita-medical-imaging-consultant-presenting-international-osteoarthritis-conference2023-03-16https://www.alacrita.com/case-studies/providing-due-diligence-pain-licensing-opportunity2019-04-29https://www.alacrita.com/blog/adapting-to-our-new-virtual-reality-in-biotechhttps://www.alacrita.com/hubfs/ink-bg.jpginkbginkbg2022-07-03https://www.alacrita.com/whitepapers/deal-watch-a-review-of-notable-deals2019-04-29https://www.alacrita.com/case-studies/gene-therapy-due-diligence-oncology-program2025-06-25https://www.alacrita.com/case-studies/anti-metastasis-mab-assessment2024-02-23https://www.alacrita.com/blog/agencies-clarify-nash-endpoints-but-dont-harmonize2019-04-30https://www.alacrita.com/blog/immune-checkpoint-inhibitors-second-act-hope-hype-or-hard-truths2025-02-12https://www.alacrita.com/virtual-biotech-consulting2025-10-25https://www.alacrita.com/scientific-due-diligencehttps://www.alacrita.com/hubfs/due-diligence-bg.jpgduediligencebgduediligencebghttps://www.alacrita.com/hubfs/Due%20Diligence%20-%20LI.jpgDueDiligenceLIDueDiligenceLI2026-02-11https://www.alacrita.com/case-studies/technical-commercial-due-diligence2023-02-15https://www.alacrita.com/case-studies/advice-for-regulatory-approval-of-a-new-ancestral-dna-device2023-11-01https://www.alacrita.com/case-studies/sales-forecast-in-metastatic-breast-cancer2023-01-31https://www.alacrita.com/case-studies/commercial-development-plan-for-crohns-disease-project2024-02-19https://www.alacrita.com/case-studies/antibody-consultant-screening-technology2019-04-29https://www.alacrita.com/blog/pipeline-asset-valuation-garbage-in-garbage-outhttps://www.alacrita.com/hubfs/AdobeStock_98004062.jpegAdobeStock98004062AdobeStock980040622020-04-23https://www.alacrita.com/case-studies/life-science-consulting-case-studies2024-06-28https://www.alacrita.com/case-studies/identifying-screening-equity-options-diagnostics-company2024-02-19https://www.alacrita.com/case-studies/due-diligence-on-a-product-for-chemotherapy-induced-anemia2024-10-14https://www.alacrita.com/whitepapers/pharma-and-biotech-due-diligence-insighthttps://www.alacrita.com/hubfs/expert-network-background.jpgexpertnetworkbackgroundexpertnetworkbackgroundhttps://www.alacrita.com/hubfs/alacrita-pharma-due-diligence-3.pngalacritapharmaduediligence3alacritapharmaduediligence3https://www.alacrita.com/hubfs/yellow_button_out.pngyellowbuttonoutyellowbuttonout2023-12-06https://www.alacrita.com/case-studies/transatlantic-payer-research-pain-therapy2019-04-29https://www.alacrita.com/case-studies/providing-high-level-gap-analysis-european-market-access2019-10-17https://www.alacrita.com/case-studies/commercialisation-roadmap-for-an-rna-array2023-11-01https://www.alacrita.com/case-studies/valuing-multinational-pharma-company-partnerships2019-04-29https://www.alacrita.com/news2023-08-29https://www.alacrita.com/contact-us/2025-05-08https://www.alacrita.com/case-studies/valuation-of-male-fertility-drug-using-monte-carlo2023-08-09https://www.alacrita.com/case-studies/due-diligence-regulatory-affairs2024-02-19https://www.alacrita.com/our-services/scientific-advisory-boards2019-08-15https://www.alacrita.com/respiratory-drug-development-consultantshttps://www.alacrita.com/hubfs/image-png-Mar-19-2024-01-16-17-1269-PM.pngimagepngMar1920240116171269PMimagepngMar1920240116171269PMhttps://www.alacrita.com/hubfs/image-png-Mar-19-2024-01-16-24-7537-PM.pngimagepngMar1920240116247537PMimagepngMar1920240116247537PM2024-03-19https://www.alacrita.com/case-studies/providing-pharmacovigilance-due-diligence-phase-lll-oncology-program2019-04-29https://www.alacrita.com/case-studies/strategic-positioning-guidance-for-rx-microbiome-product2022-06-23https://www.alacrita.com/blog/zytiga-practice-changing-clinical-news-home-run2019-04-29https://www.alacrita.com/case-studies/partner-outreach-for-asian-pharma-companies2023-01-20https://www.alacrita.com/case-studies/assessing-oral-delivery-biopharmaceuticals2019-04-29https://www.alacrita.com/case-studies/technical-and-market-risk-assessment-for-a-private-equity-firm2024-08-06https://www.alacrita.com/case-studies/regulatory-strategy-for-a-novel-drug-delivery-technology2023-08-18https://www.alacrita.com/case-studies/designing-and-monitoring-anti-ngf-antibody-imaging-endpoints2023-08-04https://www.alacrita.com/case-studies/due-diligence-on-a-bladder-cancer-gene-therapy2023-01-31https://www.alacrita.com/news/alastair-southwell-promoted-to-managing-partner2023-03-16https://www.alacrita.com/case-studies/technical-and-commercial-due-diligence-of-antibody-against-metastatic-cancers2023-11-16https://www.alacrita.com/news/bill-slichenmyer-alacrita-partner-reflects-on-sitc-2016-conference-2https://www.alacrita.com/hubfs/Imported_Blog_Media/29-dec-1-300x240.jpg29dec1300x24029dec1300x240https://www.alacrita.com/hubfs/Imported_Blog_Media/29-dec-2-300x119.jpg29dec2300x11929dec2300x119https://www.alacrita.com/hubfs/Imported_Blog_Media/29-dec-3-300x182.jpg29dec3300x18229dec3300x1822023-03-16https://www.alacrita.com/case-studies/mhra-scientific-advice-for-a-uk-phii-trial-in-primary-sclerosing-cholangitis2019-11-05https://www.alacrita.com/case-studies/an-ex-us-business-development-strategy2019-04-29https://www.alacrita.com/case-studies/valuation-of-pipeline-for-fundraising-activities2019-08-23https://www.alacrita.com/blog/obesity-beyond-getting-slim-quick-glp-1shttps://www.alacrita.com/hubfs/LI%20-%20Obesity%20Post%20.jpgLIObesityPostLIObesityPosthttps://www.alacrita.com/hubfs/uric-acid-signaling.pnguricacidsignalinguricacidsignalinghttps://www.alacrita.com/hubfs/Obesity%20Pipeline.pngObesityPipelineObesityPipeline2024-03-20https://www.alacrita.com/blog/whats-the-value-of-a-biotech-valuationhttps://www.alacrita.com/hubfs/blackboard.jpgblackboardblackboard2022-11-30https://www.alacrita.com/case-studies/valuation-of-deal-for-prophylactic-mabs-against-sars-cov-22023-11-15https://www.alacrita.com/case-studies/provision-of-support-for-creating-an-investor-prospectus2024-02-19https://www.alacrita.com/news/anthony-walker-comments-on-car-t-therapy-in-nature2019-04-29https://www.alacrita.com/case-studies/qpcr-diagnostic-platform-business-plan2024-02-19https://www.alacrita.com/case-studies/market-access-plan-for-orphan-disease-drug2023-07-27https://www.alacrita.com/cell-therapy-consultinghttps://www.alacrita.com/hubfs/image-png-Aug-15-2022-05-03-33-32-PM.pngimagepngAug15202205033332PMimagepngAug15202205033332PMhttps://www.alacrita.com/hubfs/image-png-Aug-15-2022-05-02-54-28-PM.pngimagepngAug15202205025428PMimagepngAug15202205025428PM2022-08-28https://www.alacrita.com/case-studies/defining-clinical-strategy-oncology2021-04-06https://www.alacrita.com/case-studies/point-care-diagnostics-due-diligence2019-04-29https://www.alacrita.com/our-services/product-development2026-02-27https://www.alacrita.com/case-studies/commercial-development-plan-for-a-car-t-therapy-in-head-and-neck-cancer2019-10-28https://www.alacrita.com/case-studies/development-strategy-business-support-early-stage-oncology-company2019-04-29https://www.alacrita.com/whitepapers/a-genomes-got-to-know-its-limitations2019-04-29https://www.alacrita.com/fibrosis-drug-development-consultantshttps://www.alacrita.com/hubfs/image-png-Feb-02-2024-12-15-51-2589-PM.pngimagepngFeb0220241215512589PMimagepngFeb0220241215512589PMhttps://www.alacrita.com/hubfs/image-png-Feb-02-2024-12-13-31-2362-PM.pngimagepngFeb0220241213312362PMimagepngFeb0220241213312362PM2024-04-11https://www.alacrita.com/pharmaceutical-expert-witness2026-03-11https://www.alacrita.com/case-studies/development-plan-for-beta-thalassemia-gene-therapy2024-02-19https://www.alacrita.com/blog/drugs-and-the-human-gut-microbiome-beyond-antibiotics2019-04-29https://www.alacrita.com/case-studies/valuation-of-viral-vector-manufacturing-spinout2022-06-23https://www.alacrita.com/blog/the-next-chapter-for-microbiome-drugshttps://www.alacrita.com/hubfs/AdobeStock_506528100.jpegAdobeStock506528100AdobeStock506528100https://www.alacrita.com/hubfs/microbiome-clinical-development.pngmicrobiomeclinicaldevelopmentmicrobiomeclinicaldevelopment2024-02-06https://www.alacrita.com/consultants/alastair-southwell2025-04-07https://www.alacrita.com/biotech-fundraising-support2025-05-08https://www.alacrita.com/case-studies/valuation-of-an-integrin-targeting-oncology-asset2023-11-29https://www.alacrita.com/case-studies/gap-analysis-us-cmc-data-package-european-submission2019-04-29https://www.alacrita.com/news/alacrita-launches-foothold-america2021-06-25https://www.alacrita.com/case-studies/medical-device-consulting2019-04-29https://www.alacrita.com/case-studies/scouting-for-assets-in-cns2024-02-19https://www.alacrita.com/blog/identifying-best-disease-indications-for-anti-fibrotic-drugs2024-02-02https://www.alacrita.com/case-studies/valuation-of-a-first-in-class-clinical-stage-small-molecule-to-treat-a-range-of-tumor-types2019-04-29https://www.alacrita.com/case-studies/european-market-access-support-for-clinical-stage-biopharma-company2024-02-19https://www.alacrita.com/case-studies/providing-in-licensing-due-diligence2024-02-19https://www.alacrita.com/case-studies/preclinical-clinical-asset-pipeline-valuation2023-08-18https://www.alacrita.com/case-studies/interim-medical-director-for-maa-submission2023-08-15https://www.alacrita.com/case-studies/accelerated-commercial-readiness-strategy-and-launch-plan2019-10-16https://www.alacrita.com/case-studies/forming-payer-advisory-boards2019-04-29https://www.alacrita.com/case-studies/due-diligence-on-a-therapeutics-company-repurposing-drugs2023-01-20https://www.alacrita.com/case-studies/antibodies2019-04-29https://www.alacrita.com/cell-gene-therapy-consulting2023-08-09https://www.alacrita.com/whitepapers/commercialization-of-cellular-therapies2020-11-11https://www.alacrita.com/case-studies/assessing-a-new-inhalation-device-and-assisting-with-partnering2024-04-02https://www.alacrita.com/case-studies/oncology-asset-valuation-for-fundraising-support2019-08-23https://www.alacrita.com/case-studies/building-target-product-profiles-and-conducting-rnpv-valuations-of-lead-development-assets2023-08-18https://www.alacrita.com/case-studies/due-diligence-for-in-licensing-opportunities-in-oncology2023-11-16https://www.alacrita.com/blog/assessing-reasonable-efforts-in-biopharmaceutical-licensing-disputes2025-08-25https://www.alacrita.com/case-studies/search-for-licensable-pharma-assets-of-financially-distressed-companies2024-07-10https://www.alacrita.com/case-studies/due-diligence-for-vc-firm2019-08-05https://www.alacrita.com/case-studies/possible-applications-of-an-immunomodulatory-therapy2023-01-31https://www.alacrita.com/medical-writing2024-10-17https://www.alacrita.com/news/anthony-walker-and-priyaanka-nanduri-attending-bioeurope-stockholm2019-04-29https://www.alacrita.com/case-studies/clinical-development-strategy-in-malignant-melanoma2024-01-23https://www.alacrita.com/blog/experts-and-witnesses-two-sides-of-the-same-coinhttps://www.alacrita.com/hubfs/black-gold-li.jpgblackgoldliblackgoldli2025-08-07https://www.alacrita.com/case-studies/blueprint-for-commercial-infrastructure-in-eu-and-us2019-10-16https://www.alacrita.com/brian-mcguinnesshttps://www.alacrita.com/hubfs/Brian-McGuinness-2.jpgBrianMcGuinness2BrianMcGuinness22026-02-11https://www.alacrita.com/case-studies/regulatory-support-to-understand-likelihood-of-approval-of-an-ophthalmology-asset2024-01-12https://www.alacrita.com/case-studies/biologics-manufacturing-support-for-a-discovery-stage-microbiome-company2022-06-21https://www.alacrita.com/case-studies/ongoing-due-diligence-support2024-02-19https://www.alacrita.com/our-services/medical-imaging2019-04-26https://www.alacrita.com/blog/pharma-due-diligence-light-versus-fullhttps://www.alacrita.com/hubfs/magnifying-glass.jpgmagnifyingglassmagnifyingglass2022-01-05https://www.alacrita.com/case-studies/assessment-blood-product2019-04-29https://www.alacrita.com/news/simon-turner-attending-ncri-cancer-conference-in-liverpool-uk2019-04-29https://www.alacrita.com/case-studies/valuation-of-a-novel-oncology-program2023-11-01https://www.alacrita.com/case-studies/providing-oncology-cell-therapy-reality-check2019-04-29https://www.alacrita.com/case-studies/due-diligence-on-reinvestment-in-vc-backed-biotech2024-02-19https://www.alacrita.com/case-studies/biotech-due-diligence2022-06-28https://www.alacrita.com/case-studies/submitting-510k-applications2019-04-29https://www.alacrita.com/case-studies/providing-regulatory-affairs-due-diligence2019-10-11https://www.alacrita.com/case-studies/oncology-due-diligence2019-07-26https://www.alacrita.com/case-studies/lnp-technology-competitive-landscape2023-08-01https://www.alacrita.com/case-studies/screening-rare-disease-licensing-opportunities2019-04-29https://www.alacrita.com/case-studies/acting-expert-observer-board2019-04-29https://www.alacrita.com/case-studies/developing-a-revenue-model-for-an-ai-application-for-gi-imaging2024-02-19https://www.alacrita.com/news/alacrita-publishes-thought-piece-on-virtual-drug-development2019-04-29https://www.alacrita.com/case-studies/assessing-phase-3b-follow-up-trial-for-pharma-licensing-opportunity2024-08-06https://www.alacrita.com/case-studies/evaluating-the-attractiveness-potential-positioning-of-a-new-kinase-inhibitor2024-01-10https://www.alacrita.com/case-studies/part-time-oncology-chief-medical-officer-medical-supplement2019-04-29https://www.alacrita.com/blog/mfn-drug-pricing-domestic-inefficiencyhttps://www.alacrita.com/hubfs/Eyes%20Wide%20Open%20v2.jpgEyesWideOpenv2EyesWideOpenv22025-07-16